WO2019213453A1 - Stem cells comprising synthetic chimeric vaccinia virus and methods of using them - Google Patents

Stem cells comprising synthetic chimeric vaccinia virus and methods of using them Download PDF

Info

Publication number
WO2019213453A1
WO2019213453A1 PCT/US2019/030488 US2019030488W WO2019213453A1 WO 2019213453 A1 WO2019213453 A1 WO 2019213453A1 US 2019030488 W US2019030488 W US 2019030488W WO 2019213453 A1 WO2019213453 A1 WO 2019213453A1
Authority
WO
WIPO (PCT)
Prior art keywords
virus
cells
population
vacv
genome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2019/030488
Other languages
English (en)
French (fr)
Inventor
Seth Lederman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA3098145A priority Critical patent/CA3098145A1/en
Priority to US17/049,741 priority patent/US20210236619A1/en
Priority to EP19797026.2A priority patent/EP3787681A4/en
Priority to AU2019262150A priority patent/AU2019262150A1/en
Priority to CN201980029672.6A priority patent/CN112261951A/zh
Priority to JP2020561064A priority patent/JP2021522789A/ja
Publication of WO2019213453A1 publication Critical patent/WO2019213453A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24161—Methods of inactivation or attenuation
    • C12N2710/24163—Methods of inactivation or attenuation by chemical treatment

Definitions

  • Poxviruses members of th ePoxviridae family
  • Poxviruses are double-stranded DNA viruses that can infect both humans and animals. Poxviruses are divided into two subfamilies based on host range.
  • the Chordopoxviridae subfamily which infects vertebrate hosts, consists of eight genera, of which four genera ( Orthopoxvirus , Parapoxvirus, Molluscipoxvirus , and Yatapoxvirus ) are known to infect humans. Smallpox is caused by infection with variola virus (VARV), a member of the genus Orthopoxvirus (OPV).
  • VARV variola virus
  • OOV Orthopoxvirus
  • the OPV genus comprises a number of genetically related and morphologically identical viruses, including camelpox virus (CMLV), cowpox virus (CPXV), ectromelia virus (ECTV,“mousepox agent”), horsepox virus (HPXV), monkeypox virus (MPXV), rabbitpox virus (RPXV), raccoonpox virus, skunkpox virus, Taterapox virus, Uasin Gishu disease virus, vaccinia virus (VACV), variola virus (VARV) and volepox virus (VPV).
  • CMLV camelpox virus
  • CPXV cowpox virus
  • ECTV cowpox virus
  • ECTV cowpox virus
  • ECTV ectromelia virus
  • HPXV horsepox virus
  • MPXV monkeypox virus
  • RPXV rabbitpox virus
  • raccoonpox virus s
  • oncolytic viruses In the ongoing search for therapeutics that are capable of eliminating or reducing tumor cells, oncolytic viruses have shown great potential in preclinical studies. These viruses are typically genetically engineered or have a natural tropism for tumor cells, so as to only replicate in and kill neoplastic cells. Among therapeutic viruses, oncolytic Vaccinia virus is one of the most promising candidates for cancer therapy.
  • JX-594 is a Vaccinia virus with TK gene deletion and GM-CSF (a cytokine able to stimulate the immune system to kill tumor cells) gene insertion and is currently undergoing phase III trials (Park SH et al.
  • cell therapies such as administration of stem cells
  • stem cell therapies have been associated with formation of malignant cancers in subjects receiving stem cell therapies. While the potential of cellular therapy in the treatment of diseases, disorders and injury is significant, the formation of tumors, such as teratomas, as a result of such treatment is an unacceptable outcome.
  • the present invention provides stem cells comprising a synthetic chimeric poxvirus (scPV), which can be used for the treatment of cancer or other infectious diseases.
  • scPV synthetic chimeric poxvirus
  • the invention relates to an isolated stem cell or population thereof comprising a synthetic chimeric poxvirus (scPV), wherein the virus is replicated and reactivated from DNA derived from synthetic DNA, the viral genome of said virus differing from a wild type genome of said virus in that it is characterized by one or more modifications.
  • scPV synthetic chimeric poxvirus
  • the invention relates to a pharmaceutical composition comprising the isolated stem cells of the invention, and a pharmaceutically acceptable carrier.
  • the invention in another aspect, relates to a method for delivering the scPV of the invention to a subject, comprising infecting the stem cells of the invention and administering the scPV-infected stem cells into the subject.
  • the invention relates to a method of treating or preventing cancer in a subject, comprising administering the stem cells of the invention or the pharmaceutical composition of the invention to the subject, to thereby contact the cancer cells of the subject with the scPV.
  • the invention relates to a method of treating a variola virus infection, comprising administering to a subject in need thereof the stem cells of the invention or the pharmaceutical composition of the invention.
  • Fig. 1A and IB Schematic representation of the linear dsDNA HPXV genome (strain MNR; Genbank Accession DQ792504).
  • A. Fig. 1A illustrates the unmodified genome sequence of HPXV genome with individual HPXV genes (purple) and the naturally occurring Aarl and Bsal sites indicated.
  • B. Fig. IB depicts the modified synthetic chimeric HPXV (scHPXV) genome that was chemically synthesized using the overlapping genomic DNA fragments (shown in red).
  • the engineered Sapl restriction sites that were used to ligate the VACV terminal hairpin loops onto the ITRs, along with the unmodified Bsal sites in the left and right ITR fragments, are also shown.
  • the Sapl sites were located in plasmid vector sites immediately to the left and right ends of the Left Inverted Terminal Repeat (LITR) and Right Inverted Terminal Repeat (RITR), respectively.
  • LITR Left Inverted Terminal Repeat
  • RVR Right Inverted Terminal Repeat
  • FIG. 2A-2C Detailed schematic representation of the modified scHPXV YFP-gpt: :095 genome and VACV (WR strain) terminal hairpin loops.
  • A. Fig. 2A depicts the modified scHPXV YFP-gpt: :095 genome.
  • the unmodified Bsal sites are shown as blue lines on the genome.
  • the novel Aval and Stul restriction sites that were created in HPXV044 (the VACV F4L homolog) are also marked (green lines).
  • Fig. 2B depicts the nucleotide sequence of the S (SEQ ID NO: 11) and F (SEQ ID NO: 12) forms of the terminal hairpin loop, and the color coding is explained in (C).
  • C. Fig. 2C depicts the secondary structure predictions of the F and S forms of terminal hairpin loops (SEQ ID NOS 12 and 11, respectively) that are covalently attached to the terminal ends of the linear dsDNA genomes of VACV. The terminal loop sequence is highlighted in green. The concatamer resolution sequence is boxed in red.
  • Fig. 3 The ⁇ 70bp VACV terminal hairpin was ligated to the left and right HPXV ITR fragments.
  • Fig. 3 depicts agarose gel electrophoresis of the left and right ITR fragments following ligation of the ⁇ 70bp terminal hairpin to the l472bp ITR fragment cut with Sapl.
  • the ligated DNAs were subsequently cut with Pvull to facilitate detection of the small change in size caused by the addition of the hairpins.
  • FIG. 4A-4B PCR analysis and restriction digestion of scHPXV YFP-gpt: :095 genomes confirm successful reactivation of scHPXV YFP-gpt: :095.
  • A. Fig. 4A depicts pulse field gel electrophoresis (PFGE) of VACV-WR and scHPXV YFP-gpt: :095 genomic DNAs. Virus DNAs was digested with Bsal , Hindlll , or left untreated, and were then separated on a 1% Seakem gold agarose gel for 14 h at l4°C at 5.7V/cm with a switch time of 1 to 10 seconds.
  • PFGE pulse field gel electrophoresis
  • Fig. 4B depicts conventional agarose gel electrophoresis of VACV-WR and scHPXV YFP-gpt: :095 genomic DNA digested with Bsal or Hindlll. DNA fragments were visualized by staining gels with SybrGold DNA stain. [0019] Fig. 5A-5C.
  • Fig. 5A depicts Illumina sequence reads that mapped to one region of the HPXV (DQ792504) genome. Only a small fraction of the reads is shown. The conflicts in the sequencing reads at pos. 96,239 and pos. 96437 are highlighted in blue and yellow, respectively.
  • Fig. 5B depicts the magnification of the Illumina sequencing reads from scHPXV YFP-gpt: :095 that mapped to HPXV (DQ792504) near pos. 96239.
  • FIG. 1 A nucleotide substitution (T96239C) was detected (refer to Table 2).
  • Figure discloses SEQ ID NOS 68-70, 69, 71, 72, 69, 73-76, 69, 77-79, 69, 69, 80, 81, 69, 82, 69, 83, 69, 84, 69, 84, 85, 69, 69, 86, 69, 69, 87, 69, 69, 69, 69, 69, 88, 69, 69, 69, 89, and 90, respectively, in order of appearance.
  • 5C depicts the magnification of the Illumina sequencing reads from scHPXV YFP-gpt: :095 that mapped to HPXV (DQ792504) at pos. 96437.
  • a nucleotide substitution (A96437C) was detected (refer to Table 2). These mutations were introduced into the clones used to assemble scHPXV YFP- gpt: :095 so as to delete undesirable Bsal recognition sites (GGTCTC).
  • Figure discloses SEQ ID NOS 91-94, 92, 95, 92, 92, 92, 96, 92, 97, 98, 92, 92, 92, 92, 99-101, 92, 102, 103, 92, 104-109, 92, 110, 92, 92, 111, 103, 112, 92, 113, 114, 92, 92, 115, and 116, respectively, in order of appearance.
  • Fig. 6A-6C ScHPXV YFP-gpt: :095 grows like other Orthopoxviruses but exhibits a small plaque phenotype in BSC-40 cells.
  • A. Fig. 6A illustrates the multi-step growth of VACV-WR, DPP 15, CPXV, and scHPXV YFP-gpt: : 095 in BSC-40 (top left panel), HeLa (top middle panel), primary HEL (top right panel), and Vero (bottom left panel) cell lines.
  • B. Fig. 6B illustrates plaque size comparisons between VACV-WR, DPP 15, CPXV, and scHPXV YFP-gpt: :095.
  • BSC-40 cells were infected with the indicated viruses and at 48 h post infection the cells were fixed and stained. The areas (in arbitrary units [A.U.]) of 24 plaques over three independent experiments were measured for each virus. Data are expressed as the mean plaque diameter. **, P ⁇ 0.01; ****, P ⁇ 0.0001.
  • C. Fig. 6C depicts plaque morphology of BSC-40 cells infected with the indicated viruses for 72 h. Cells were fixed, stained, and scanned for visualization.
  • FIG. 7 A graphical representation of the % weight loss over time after administration of various compositions and doses to mice.
  • the depicted data are generated from groups of 5 female BALB/c mice that are inoculated with the indicated dose of scHPXV YFP-gpt: :095 (also designated as scHPXV(AHPXV_095/J2R) or scHPXV (yfp/gpt)), scHPXV (wt), Dryvax DPP15, or VACV WR in 10m1 of PBS.
  • Mice are weighed daily for 28 days and any that lost >25% of their initial weight are euthanized. Data points represent mean scores, and error bars represent standard deviation.
  • FIG. 8A and 8B Graphical representations of the % weight loss over time after administration of various compositions and doses to mice.
  • the depicted data are generated from mice that are previously vaccinated (Fig. 10) and who are then challenged with a lethal dose of VACV WR (10 6 PFU) intranasally.
  • Fig. 8A shows the weight changes and
  • Fig. 8B shows the clinical scores in mice recorded daily for 13 days. Any mice that lost >25% of their initial weight are euthanized. Mice are assigned a clinical score based upon the appearance of ruffled fur, hunched posture, difficulty breathing, and decreased mobility. Data points represent mean differences in weights or scores, and error bars represent standard deviation. ⁇ indicate the number of mice that succumb to the VACV infection on a given day.
  • FIG. 9 Graphical representation of the % survival over time after administration of various compositions and doses to mice. The depicted data are generated from mice that are previously vaccinated (Fig. 7) and who are then challenged with a lethal dose of VACV WR (10 6 PFU) intranasally. Fig. 9 shows survival curves of mice who are challenged intranasally with a lethal dose of VACV WR (10 6 PFU). ⁇ indicate the number of mice that succumb to the VACV infection on the indicated day.
  • FIG. 10A and 10B Characterization of VACV-HPXV hybrid viruses. Fig. 10A.
  • HPXV inserts in VACV strain WR were sequenced using an Illumina platform, assembled, and LAGAN and“Base-by-Base” software were used to align and generate the maps shown. Places where VACV sequences (white) have been replaced by HPXV sequences are color coded according to the difference.
  • Fig. 10B A PCR-based screening approach for identifying hybrid and reactivated viruses. Following PCR amplification, the products were digested with Bsal to differentiate VACV sequences (which cut) from HPXV (which do not cut). The VACV/HPXV hybrids exhibit a mix of Bsal sensitive and resistant sites whereas the reactivated scHPXV YFP-gpt: :095 clone is fully Bsal resistant.
  • FIG. 11A-11C Growth properties of scHPXV versus scHPXV YFP-gpt::095. Fig.
  • FIG. 11 A Plaque size measurements. Homologous recombination was used to replace the YFP-gpt locus in scHPXV YFP-gpt: :095 with thymidine kinase gene sequences. This produced a virus with a fully wild-type complement of HPXV genes (scHPXV). BSC-40 cells were infected with the indicated viruses and cultured for three days. The dishes were stained and the plaque areas measured using a scanned digital image. Statistically significant differences are noted ****/' ⁇ 0.0001).
  • Fig. 11B Plaque images.
  • FIG. 11C Multi-step virus growth in culture.
  • the indicated cell lines were infected with scHPXV or scHPXV YFP-gpt: :095 at a multiplicity of infection of 0.01, the virus harvested at the indicated times, and titrated on BSC-40 cells in triplicate. No significant differences in the growth of these viruses were detected in these in vitro assays.
  • FIG. 12 Schematic representation of the linear dsDNA VACV genome strain ACAM2000; Genbank Accession AY313847.
  • Fig. 12 depicts the modified VACV ACAM2000 genome that was used to chemically synthesize large ds DNA fragments.
  • the overlapping scVACV ACAM2000 genomic fragments are depicted in blue.
  • the engineered Bsal restriction sites that were not silently mutated in the Left Inverted Terminal Repeat (LITR) and the Right Inverted Terminal Repeat (RITR), are also shown.
  • LITR Left Inverted Terminal Repeat
  • RVR Right Inverted Terminal Repeat
  • FIG. 13A-13C Detailed schematic representation of the first -1500-3000 bp of the published genomes of (A) VACV WR strain and (B) VACV ACAM2000.
  • the tandem repeat regions are clearly indicated in red (70 bp repeat), blue (125 bp repeat) and green (54 bp repeat) boxes.
  • the ORF corresponding to gene C23L is also indicated in each of the genomes.
  • C Schematic representation of the direct repeat region containing 70 bp repeat sequences in VACV WR. This sequence was synthesized to contain a Sapl restriction site at the 5’ terminus and an Nhel restriction site at the 3’ terminus to ligate the hairpin/duplex piece and the VACV ACAM2000 ITR fragments, respectively.
  • Fig. 14 Assembly of vaccinia virus terminal hairpin loop with duplex DNA to the first 70 bp repeat sequence.
  • Gel electrophoresis of duplex DNA (lane 2) and hairpin DNA alone (lane 3) and following ligation (lane 4) are depicted.
  • the ligated product (arrow) was subsequently excised from the gel and purified, so that it could be ligated to a 70 bp repeat sequence to mimic the sequence of the wtVACV ACAM2000 sequence.
  • Fig. 15 Growth properties of scVACV ACAM2000-WR DUP/HP in vitro. Multi-step growth kinetics measured in monkey kidney epithelial cells (BSC-40). The cells were infected at a multiplicity of infection 0.03, the virus was harvested at the indicated times, and the virus was titrated on BSC-40 cells. The data represent three independent experiments. The error bars indicate standard error of the mean (SEM).
  • Fig. 16 Growth properties of scVACV ACAM2000-WR DUP/HP and scVACV ACAM2000-ACAM2000 DUP/HP in vitro, compared to scVACV ACAM2000-WR DUP/HP and scVACV ACAM2000-ACAM2000 DUP/HP where the YFP-gpt marker has been replaced with the J2R gene sequence (VAC WRAJ2R) and wtVACV ACAM2000.
  • Fig. 17 Restriction endonuclease mapping of reactivated scVACV ACAM2000-WR
  • scVACV ACAM2000-WR DUP/HP clones Pulsed field gel electrophoretic analysis. Two independent scVACV ACAM2000-WR DUP/HP clones plus a VACV WR control, where the YFP-gpt marker has been replaced with the J2R gene sequence (VAC WRAJ2R) and a wtVACV ACAM2000 control (VAC_ACAM2000) were purified and then left either undigested, digested with Bsal, Hindlll , or Notl and Pvul. The expected absence of nearly all of the Bsal sites in the scVACV
  • ACAM2000 clones was apparent. Minor differences in the Hindlll digested scVACV ACAM2000 genomic DNA compared to VACV WRAJ2R and VACV_ACAM2000 were observed. Genomic DNA digested with Notl and Pvul excises the 70bp tandem repeat fragments found at the left and right ITR sequences. In VACV WRAJ2R the -size of the 70bp repeats is close to 3.6 kbp. Interestingly, in the two independent scVACV ACAM2000 clones two different sized bands corresponding to the 70bp tandem repeat were observed (marked with an *), even though a full-length 70bp tandem repeat element was ligated to the ITR fragments. When ACAM2000 genomic DNA was digested with Notl and Pvul, a band at -4.7 kbp was observed, which may indicate the size of the 70bp repeats in ACAM2000. DETAILED DESCRIPTION OF THE DISCLOSURE
  • wild type virus As used herein, the terms“wild type virus”,“wild type genome”,“wild type protein,” or“wild type nucleic acid” refer to a sequence of amino or nucleic acids that occurs naturally within a certain population (e.g., a particular viral species, etc.).
  • chimeric or“engineered” or“modified” e.g., chimeric poxvirus, engineered polypeptide, modified polypeptide, engineered nucleic acid, modified nucleic acid
  • grammatical variations thereof are used interchangeably herein to refer to a non-native sequence that has been manipulated to have one or more changes relative a native sequence.
  • synthetic virus refers to a virus initially derived from synthetic DNA
  • the synthetic virus refers to a virus where substantially all of the viral genome is initially derived from synthetic DNA (e.g., chemically synthesized DNA, PCR amplified DNA, engineered DNA, polynucleotides comprising nucleoside analogs, etc., or combinations thereof).
  • the synthetic virus is derived from chemically synthesized DNA.
  • position as used herein is meant a location in the genome sequence. Corresponding positions are generally determined through alignment with other parent sequences.
  • residue in the context of a polypeptide refers to an amino- acid unit in the linear polypeptide chain. It is what remains of each amino acid, i.e -NH-CHR- C-, after water is removed in the formation of the polypeptide from a-amino-acids, i.e. NH2- CHR-COOH.
  • polynucleotide refers to chains of nucleotides of any length, and include DNA and RNA.
  • the nucleotides can be deoxyribonucleotides, ribonucleotides, modified nucleotides or bases, and/or their analogs, or any substrate that can be incorporated into a chain by DNA or RNA polymerase.
  • a polynucleotide may comprise modified nucleotides, such as methylated nucleotides and their analogs. If present, modification to the nucleotide structure may be imparted before or after assembly of the chain.
  • the sequence of nucleotides may be interrupted by non-nucleotide components.
  • a polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component.
  • Other types of modifications include, for example,“caps”, substitution of one or more of the naturally occurring nucleotides with an analog; internucleotide modifications such as, for example, those with uncharged linkages (e.g., methyl phosphonates, phosphotriesters, phosphoamidates, carbamates, etc.) and with charged linkages (e.g., phosphorothioates, phosphorodithioates, etc.); those containing pendant moieties, such as, for example, proteins (e.g., nucleases, toxins, antibodies, signal peptides, poly-L-lysine, etc.); those with intercalators (e.g., acridine, psoralen, etc.); those containing chelators (e.g., metal
  • any of the hydroxyl groups ordinarily present in the sugars may be replaced, for example, by phosphonate groups, phosphate groups, protected by standard protecting groups, or activated to prepare additional linkages to additional nucleotides, or may be conjugated to solid supports.
  • the 5’ and 3’ terminal OH can be phosphorylated or substituted with amines or organic capping group moieties of from 1 to 20 carbon atoms.
  • Other hydroxyls may also be derivatized to standard protecting groups.
  • Polynucleotides can also contain analogous forms of ribose or deoxyribose sugars that are generally known in the art, including, for example, 2’-0-methyl-, 2’-0-allyl, T - fluoro- or 2’-azido-ribose, carbocyclic sugar analogs, alpha- or beta-anomeric sugars, epimeric sugars such as arabinose, xyloses or lyxoses, pyranose sugars, furanose sugars, sedoheptuloses, acyclic analogs and abasic nucleoside analogs such as methyl riboside.
  • One or more phosphodiester linkages may be replaced by alternative linking groups.
  • linking groups include, but are not limited to, embodiments wherein phosphate is replaced by P(0)S(“thioate”), P(S)S (“dithioate”), (0)NR 2 (“amidate”), P(0)R, P(0)0R ⁇ CO or CH 2 (“formacetal”), in which each R or R’ is independently H or substituted or unsubstituted alkyl (1-20 C) optionally containing an ether (-0-) linkage, aryl, alkenyl, cycloalkyl, cycloalkenyl or araldyl. Not all linkages in a polynucleotide need be identical. The preceding description applies to all polynucleotides referred to herein, including RNA and DNA.
  • polypeptide oligopeptide
  • peptide protein
  • the terms “polypeptide”, “oligopeptide”, “peptide” and “protein” are used interchangeably herein to refer to chains of amino acids of any length.
  • the chain may be linear or branched, it may comprise modified amino acids, and/or may be interrupted by non-amino acids.
  • the terms also encompass an amino acid chain that has been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component.
  • polypeptides containing one or more analogs of an amino acid including, for example, unnatural amino acids, etc.
  • the polypeptides can occur as single chains or associated chains.
  • the term“homologous,” when modified with an adverb such as“highly,” may refer to sequence similarity and may or may not relate to a common evolutionary origin.
  • Heterologous in all its grammatical forms and spelling variations, may refer to a DNA which is non-native to the virus. It means derived from a different species or a different strain than the DNA of the organism to which the DNA is described as heterologous relative to.
  • the viral genome of the scPV comprises heterologous terminal hairpin loops. Said heterologous terminal hairpin loops can be derived from a different virus species or from a different virus strain.
  • sequence similarity in all its grammatical forms, refers to the degree of identity or correspondence between nucleic acid or amino acid sequences that may or may not share a common evolutionary origin.
  • Percent (%) sequence identity or“sequence % identical to” with respect to a reference polypeptide (or nucleotide) sequence is defined as the percentage of amino acid residues (or nucleic acids) in a candidate sequence that are identical with the amino acid residues (or nucleic acids) in the reference polypeptide (nucleotide) sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.
  • a“host cell” includes an individual cell or cell culture that can be or has been a recipient for vector(s) for incorporation of polynucleotide inserts.
  • Host cells include progeny of a single host cell, and the progeny may not necessarily be completely identical (in morphology or in genomic DNA complement) to the original parent cell due to natural, accidental, or deliberate mutation.
  • a host cell includes cells transfected and/or transformed in vivo with a nucleic acid of this disclosure.
  • vector means a construct, which is capable of delivering, and, preferably, expressing, one or more gene(s) or sequence(s) of interest in a host cell.
  • vectors include, but are not limited to, viral vectors, naked DNA or RNA expression vectors, plasmid, cosmid or phage vectors, DNA or RNA expression vectors associated with cationic condensing agents, DNA or RNA expression vectors encapsulated in liposomes, and certain eukaryotic cells, such as producer cells.
  • isolated molecule (where the molecule is, for example, a polypeptide, a polynucleotide, or fragment thereof) is a molecule that by virtue of its origin or source of derivation (1) is not associated with one or more naturally associated components that accompany it in its native state, (2) is substantially free of one or more other molecules from the same species (3) is expressed by a cell from a different species, or (4) does not occur in nature.
  • a molecule that is chemically synthesized, or expressed in a cellular system different from the cell from which it naturally originates will be “isolated” from one or many of its naturally associated components.
  • a molecule also may be rendered substantially free of from one or many of naturally associated components by isolation, using purification techniques well known in the art.
  • Molecule purity or homogeneity may be assayed by a number of means well known in the art.
  • the purity of a polypeptide sample may be assayed using polyacrylamide gel electrophoresis and staining of the gel to visualize the polypeptide using techniques well known in the art.
  • higher resolution may be provided by using HPLC or other means well known in the art for purification.
  • isolated in the context of viruses, refers to a virus that is derived from a single parental virus.
  • a virus can be isolated using routine methods known to one of skill in the art including, but not limited to, those based on plaque purification and limiting dilution.
  • MOI multiplicity of infection
  • purify refers to the removal, whether completely or partially, of at least one impurity from a mixture containing the polypeptide and one or more impurities, which thereby improves the level of purity of the polypeptide in the composition (i.e., by decreasing the amount (ppm) of impurity(ies) in the composition).
  • purified in the context of viruses refers to a virus which is substantially free of cellular material and culture media from the cell or tissue source from which the virus is derived. The language “substantially free of cellular material” includes preparations of virus in which the virus is separated from cellular components of the cells from which it is isolated or recombinantly produced.
  • virus that is substantially free of cellular material includes preparations of protein having less than about 30%, 20%, 10%, or 5% (by dry weight) of cellular protein (also referred to herein as a "contaminating protein").
  • the virus is also substantially free of culture medium, i.e., culture medium represents less than about 20%, 10%, or 5% of the volume of the virus preparation.
  • a virus can be purified using routine methods known to one of skill in the art including, but not limited to, chromatography and centrifugation.
  • substantially pure refers to material which is at least 50% pure (i.e., free from contaminants), more preferably, at least 90% pure, more preferably, at least 95% pure, yet more preferably, at least 98% pure, and most preferably, at least 99% pure.
  • the terms“patient”,“subject”, or“individual” are used interchangeably herein and refer to either a human or a non-human animal. These terms include mammals, such as humans, primates, livestock animals (including bovines, porcines, camels, etc.), companion animals (e.g., canines, felines, etc.) and rodents (e.g., mice and rats).
  • the terms “prevent”, “preventing” and “prevention” refer to the delay of the recurrence or onset of disease, or a reduction in one or more symptoms of a disease (e.g., a poxviral infection) in a subject as a result of the administration of a therapy (e.g., a prophylactic or therapeutic agent).
  • a therapy e.g., a prophylactic or therapeutic agent
  • prevent refers to the inhibition or a reduction in the development or onset of an infection (e.g., a poxviral infection or a condition associated therewith), or the prevention of the recurrence, onset, or development of one or more symptoms of an infection (e.g., a poxviral infection or a condition associated therewith), in a subject resulting from the administration of a therapy (e.g., a prophylactic or therapeutic agent), or the administration of a combination of therapies (e.g., a combination of prophylactic or therapeutic agents).
  • a therapy e.g., a prophylactic or therapeutic agent
  • a combination of therapies e.g., a combination of prophylactic or therapeutic agents
  • treatment refers to treating a condition or patient and refers to taking steps to obtain beneficial or desired results, including clinical results.
  • infections e.g., a poxviral infection or a variola virus infection
  • treatment refers to the eradication or control of the replication of an infectious agent (e.g., the poxvirus or the variola virus), the reduction in the numbers of an infectious agent (e.g., the reduction in the titer of the virus), the reduction or amelioration of the progression, severity, and/or duration of an infection (e.g., a poxviral/ variola infection or a condition or symptoms associated therewith), or the amelioration of one or more symptoms resulting from the administration of one or more therapies (including, but not limited to, the administration of one or more prophylactic or therapeutic agents).
  • an infectious agent e.g., the poxvirus or the variola virus
  • the reduction in the numbers of an infectious agent e.g., the reduction in the titer of the virus
  • treatment refers to the eradication, removal, modification, or control of primary, regional, or metastatic cancer tissue that results from the administration of one or more therapeutic agents of the disclosure.
  • such terms refer to minimizing or delaying the spread of cancer resulting from the administration of one or more therapeutic agents of the invention to a subject with such a disease.
  • such terms refer to elimination of disease-causing cells.
  • administering or“administration of’ a substance, a compound or an agent to a subject can be carried out using one of a variety of methods known to those skilled in the art.
  • a compound or an agent can be administered sublingually or intranasally, by inhalation into the lung or rectally.
  • Administering can also be performed, for example, once, a plurality of times, and/or over one or more extended periods.
  • the administration includes both direct administration, including self-administration, and indirect administration, including the act of prescribing a drug.
  • a physician who instructs a patient to self-administer a drug, or to have the drug administered by another and/or who provides a patient with a prescription for a drug is administering the drug to the patient.
  • Poxviruses are large (-200 kbp) DNA viruses that replicate in the cytoplasm of infected cells.
  • the Orthopoxvirus (OPV) genus comprises a number of poxviruses that vary greatly in their ability to infect different hosts.
  • Vaccinia virus (VACV) for example, can infect a broad group of hosts, whereas variola virus (VARV), the causative agent of smallpox, only infects humans.
  • VACV variola virus
  • a feature common to many, if not all poxviruses, is their ability to non- genetically“reactivate” within a host.
  • Non-genetic reactivation refers to a process wherein cells infected by one poxvirus can promote the recovery of a second“dead” virus (for example one inactivated by heat) that would be non-infectious on its own.
  • Purified poxvirus DNA is not infectious because the virus life cycle requires transcription of early genes via the virus-encoded RNA polymerases that are packaged in virions. However, this deficiency can be overcome if virus DNA is transfected into cells previously infected with a helper poxvirus, providing the necessary factors needed to transcribe, replicate, and package the transfected genome in trans (Sam CK, Dumbell KR.
  • Yao and Evans described a method in which the high-frequency recombination and replication reactions catalyzed by a Leporipoxvirus , Shope fibroma virus (SFV), can be coupled with an SFV-catalyzed reactivation reaction, to rapidly assemble recombinant vaccinia strains using multiple overlapping fragments of viral DNA (Yao XD, Evans DH. High-frequency genetic recombination and reactivation of orthopoxviruses from DNA fragments transfected into leporipoxvirus-infected cells. Journal of Virology. 2003 ;77(l3):7281-90).
  • One aspect of the invention provides stem cells comprising a synthetic chimeric poxvirus (scPV), which can be used for the treatment of cancer and infectious diseases.
  • the functional synthetic chimeric poxvirus (scPV) comprised within the stem cells is initially replicated and assembled from chemically synthesized DNA.
  • the scPV can be any poxvirus whose genome has been sequenced or can be sequenced in large part or for which a natural isolate is available.
  • the viruses that may be produced in accordance with various embodiments of the methods of the invention can be any poxvirus whose genome has been sequenced in large part or for which a natural isolate is available.
  • an scPV of the invention may be based on the genome sequences of naturally occurring strains, variants or mutants, mutagenized viruses or genetically engineered viruses.
  • the viral genome of an scPV of the invention comprises one or more modifications relative to the wild type genome or base genome sequence of said virus.
  • the modifications may include, for example, one or more deletions, insertions, substitutions, or combinations thereof. It is understood that the modifications may be introduced in any number of ways commonly known in the art.
  • a “stem cell” is any totipotent, pluripotent or multipotent cell that has the ability to differentiate into multiple different types of cells (e.g., terminally differentiated cells).
  • the term“stem cell”, as used herein, refers to a subset of progenitors that have the capacity or potential, under particular circumstances, to differentiate to a more specialized or differentiated phenotype, and which retains the capacity, under certain circumstances, to proliferate without substantially differentiating.
  • the term stem cell refers generally to a naturally occurring mother cell whose descendants (progeny) specialize, often in different directions, by differentiation, e.g., by acquiring completely individual characters, as occurs in progressive diversification of embryonic cells and tissues.
  • a differentiated cell may derive from a multipotent cell which itself is derived from a multipotent cell, and so on. While each of these multipotent cells may be considered stem cells, the range of cell types each can give rise to may vary considerably. Some differentiated cells also have the capacity to give rise to cells of greater developmental potential. Such capacity may be natural or may be induced artificially upon treatment with various factors. In many biological instances, stem cells are also“multipotent” because they can produce progeny of more than one distinct cell type, but this is not required for“stem-ness.” Self-renewal is the other classical part of the stem cell definition, and it is essential as used in this invention.
  • Stem cells may divide asymmetrically, with one daughter retaining the stem state and the other daughter expressing some distinct other specific function and phenotype.
  • some of the stem cells in a population can divide symmetrically into two stems, thus maintaining some stem cells in the population as a whole, while other cells in the population give rise to differentiated progeny only.
  • cells that begin as stem cells might proceed toward a differentiated phenotype, but then“reverse” and re-express the stem cell phenotype, a term often referred to as “dedifferentiation” or “reprogramming” or“retrodifferentiation”.
  • Stem cells include any type of stem cell, including embryonic stem cells (ES) cells, post-natal stem cells (e.g. from the umbilical cord and placenta), fetal stem cells and adult stem cells (i.e., somatic stem cells). Other types, such as induced pluripotent stem cells (iPSCs), are produced in the lab by reprogramming adult cells to express ES characteristics.
  • the adult stem cells are mesenchymal stem cells.
  • the adult stem cells are tissue or organ specific stem cells such as neuronal stem cells, vascular stem cells, or epidermal stem cells.
  • the adult stem cells are mesenchymal stem cells (MSC).
  • Mesenchymal stem cells can be obtained from a variety of sources such as bone marrow, umbilical cord blood, and adipose tissue (adipose-tissue derived stem cells).
  • sources of stem cells are human umbilical vein endothelial cells (EtUVEC), and primary human cutaneous microvascular endothelial cells (HCMEC).
  • EtUVEC human umbilical vein endothelial cells
  • HCMEC primary human cutaneous microvascular endothelial cells
  • Analogous non-human stem cells can be obtained from similar non-human sources as well.
  • Stem cells for use in one aspect of the invention may be primary cells or cells that have been maintained in cell culture for an extended period.
  • the stem cells may be obtained from any animal type, including human.
  • the stem cell is a human cell.
  • embryonic stem cells are stem cells obtained from an embryo that is typically six weeks old or less.
  • Totipotent human embryonic stem cells hESC
  • Pluripotent human primordial germ cells hEG
  • fetal stem cells refer to any stem cell that is obtained prenatally from a fetus that is typically greater that 6 weeks old.
  • adult stem cells refers to any stem cell that is obtained from a post-natal subject. Typically, the subject is a full grown adult.
  • Exemplary adult stem cells include, but are not limited to, cells harvested from organs such as fat, muscle or bone marrow.
  • the stem cells are autologous, i.e., the cells are obtained or derived from the subject’s own stem cells.
  • the stem cells of the invention are obtained or derived from a subject who is in need of therapeutic treatment for a cell proliferative disorder (tumor or cancer). The subject may already have the cell proliferative disorder or be at risk for the disorder.
  • the stem cells are allogeneic, i.e., the cells are obtained or derived from a donor whose human leukocyte antigens (HLA) are acceptable matches to the subject’s.
  • HLA human leukocyte antigens
  • the invention relates to an isolated stem cell or population thereof comprising a synthetic chimeric poxvirus (scPV), wherein the virus is replicated and reactivated from DNA derived from synthetic DNA, the viral genome of said virus differing from a wild type genome of said virus in that it is characterized by one or more modifications.
  • scPV synthetic chimeric poxvirus
  • the invention relates to an isolated stem cell or population thereof comprising a synthetic chimeric orthopoxvirus, wherein the virus is replicated and reactivated from DNA derived from synthetic DNA, the viral genome of said virus differing from a wild type genome of said virus in that it is characterized by one or more modifications.
  • the invention relates to an isolated stem cell or population thereof comprising a synthetic chimeric vaccinia virus, wherein the virus is replicated and reactivated from DNA derived from synthetic DNA, the viral genome of said virus differing from a wild type genome of said virus in that it is characterized by one or more modifications.
  • the invention relates to an isolated stem cell or population thereof comprising a synthetic chimeric horsepox virus, wherein the virus is replicated and reactivated from DNA derived from synthetic DNA, the viral genome of said virus differing from a wild type genome of said virus in that it is characterized by one or more modifications.
  • the stem cell of the invention is a non-cancer stem cell.
  • VACV ACAM2000 strain NYCBH, clone ACAM2000
  • VACV AC AM2000 terminal hairpin loop sequences the terminal hairpin loops are based on the VACV ACAM2000 terminal hairpin loop sequences.
  • the poxvirus belongs to the Chordopoxvirinae subfamily. In some embodiments, the poxvirus belongs to a genus of Chordopoxvirinae subfamily selected from Avipoxvirus, Capripoxvirus, Cervidpoxvirus, Crocodylipoxvirus, Leporipoxvirus, Molluscipoxvirus, Orthopoxvirus, Parapoxvirus, Suipoxvirus, or Yatapoxvirus. In some embodiments, the poxvirus is an Orthopoxvirus.
  • the Orthopoxvirus is selected from camelpox virus (CMLV), cowpox virus (CPXV), ectromelia virus (ECTV, “mousepox agent”), HPXV, monkeypox virus (MPXV), rabbitpox virus (RPXV), raccoonpox virus, skunkpox virus, Taterapox virus, Uasin Gishu disease virus, vaccinia virus (VACV), variola virus (VARV) and volepox virus (VPV).
  • the poxvirus is an HPXV.
  • the poxvirus is a VACV.
  • the poxvirus is a Parapoxvirus .
  • the Parapoxvirus is selected from orf virus (ORFV), pseudocowpox virus (PCPV), bovine popular stomatitis virus (BPSV), squirrel parapoxvirus (SPPV), red deer parapoxvirus, Ausdyk virus, Chamois contagious ecythema virus, reindeer parapoxvirus, or sealpox virus.
  • ORFV orf virus
  • PCPV pseudocowpox virus
  • BPSV bovine popular stomatitis virus
  • SPPV squirrel parapoxvirus
  • red deer parapoxvirus Ausdyk virus
  • Chamois contagious ecythema virus Chamois contagious ecythema virus
  • reindeer parapoxvirus or sealpox virus.
  • the poxvirus is a Molluscipoxvirus.
  • the Molluscipoxvirus is molluscum contagiousum virus (MCV).
  • the poxvirus is a Yatapoxvirus
  • the Yatapoxvirus is selected from Tanapox virus or Yaba monkey tumor virus (YMTV).
  • the poxvirus is a Capripoxvirus.
  • the Capripoxvirus is selected from sheepox, goatpox, or lumpy skin disease virus.
  • the poxvirus is a Suipoxvirus.
  • the Suipoxvirus is swinepox virus.
  • the poxvirus is a Leporipoxvirus.
  • the Leporipoxvirus is selected from myxoma virus, Shope fibroma virus (SFV), squirrel fibroma virus, or hare fibroma virus. New poxviruses (e.g., Orthopoxviruses) are still being constantly discovered. It is understood that an scPV of the various aspects of the invention may be based on such a newly discovered poxvirus.
  • the scPV is a CMLV whose genome is based on a published genome sequence (e.g., strain CMS (Genbank Accession AY009089.1)).
  • the scPV is a CPXV whose genome is based on a published genome sequence (e.g., strain Brighton Red (Genbank Accession AF482758), strain GRI-90 (Genbank Accession X94355)).
  • the scPV is a ECTV whose genome is based on a published genome sequence (e.g. strain Moscow (Genbank Accession NC_004l05)).
  • the scPV is a MPXV whose genome is based on a published genome sequence (e.g., strain Zaire-96-l-l6 (Genbank Accession AEG 80138)). In some aspects, the scPV is a RPXV whose genome is based on a published genome sequence (e.g. strain Utrecht (Genbank Accession AY484669)). In some aspects, the scPV is a Taterapox virus whose genome is based on a published genome sequence (e.g., strain Dahomey 1968 (Genbank Accession NC_00829l)).
  • Chemical viral genome synthesis also opens up the possibility of introducing a large number of useful modifications to the resulting genome or to specific parts of it.
  • the modifications may improve ease of cloning to generate the virus, provide sites for introduction of recombinant gene products, improve ease of identifying reactivated viral clones and/or confer a plethora of other useful features (e.g., introducing a desired antigen, producing an oncolytic virus, etc.).
  • the modifications may include the attenuation or deletion of one or more virulence factors.
  • the modifications may include the addition or insertion of one or more virulence regulatory genes or gene-encoding regulatory factors.
  • the invention provides polynucleotides for producing a synthetic chimeric horsepox virus (scHPXV).
  • the scHPXV genome may be based on the genome sequence described for HPXV strain MNR-76 (SEQ ID NO: 49) (Tulman ER, Delhon G, Afonso CL, Lu Z, Zsak L, Sandybaev NT, et al. Genome of horsepox virus. Journal of Virology. 2006;80(l8):9244-58). This genome sequence is incomplete and appears not to include the sequence of the terminal hairpin loops.
  • terminal hairpin loops from vaccinia virus can be ligated onto the ends of the HPXV genome to produce functional scHPXV particles using the methods of the invention.
  • the HPXV genome may be divided into 10 overlapping fragments as described in the working examples of the disclosure and shown in Table 1. In some embodiments, the genome may be divided into 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 overlapping fragments. In some embodiments, the entire genome may be provided as one fragment. The genomic locations of the exemplary overlapping fragments and fragment sizes are shown in Table 1. Table 2 shows some of the modifications that may be made in these fragments relative to the base sequence.
  • polynucleotides of one aspect of the invention comprise nucleic acids sequences that are at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NOs: 1-10.
  • an isolated polynucleotide of the invention comprises a variant of these sequences, wherein such variants can include missense mutations, nonsense mutations, duplications, deletions, and/or additions.
  • SEQ ID NO: 11 and SEQ ID NO: 12 depict the nucleotide sequences of VACV (WR strain) terminal hairpin loops.
  • the terminal hairpin loops comprise nucleic acid sequences that are at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 11 or SEQ ID NO: 12.
  • the invention provides polynucleotides for producing a synthetic chimeric vaccinia virus (scVACV).
  • scVACV synthetic chimeric vaccinia virus
  • the scVACV genome may be based on the published genome sequence described for VACV strain NYCBH clone ACAM2000 (GenBank accession AY313847; Osborne JD et al. Vaccine. 2007; 25(52):8807- 32). This genome sequence is incomplete and appears not to include the sequence of the terminal hairpin loops and only four 54bp repeat sequences were identified.
  • terminal hairpin loops from vaccinia virus (VACV) strain WR can be ligated onto the ends of the VACV genome strain NYCBH clone ACAM2000 to produce functional scVACV particles using the methods of the disclosure.
  • the terminal hairpin loops from vaccinia virus (VACV) strain ACAM2000 can be ligated onto the ends of the VACV genome strain NYCBH clone ACAM2000 to produce functional scVACV particles using the methods of the disclosure.
  • the scVACV genome may be divided into 9 overlapping fragments as described in the working examples of the disclosure and shown in Table 4.
  • the VACV genome may be divided into 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 overlapping fragments.
  • the entire genome may be provided as one fragment.
  • the fragment sizes are shown in Table 4.
  • the polynucleotides of one aspect of the invention comprise nucleic acids sequences that are at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NOs: 54-62.
  • an isolated polynucleotide of the invention comprises a variant of these sequences, wherein such variants can include missense mutations, nonsense mutations, duplications, deletions, and/or additions.
  • SEQ ID NO: 11 and SEQ ID NO: 12 depict the nucleotide sequences of VACV (WR strain) terminal hairpin loops.
  • SEQ ID NO: 117 and SEQ ID NO: 118 depict the nucleotide sequences of VACV (ACAM2000 strain) terminal hairpin loops.
  • the terminal hairpin loops comprise nucleic acid sequences that are at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 11 or to SEQ ID NO: 12.
  • the terminal hairpin loops comprise nucleic acid sequences that are at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 117 or to SEQ ID NO: 118.
  • the terminal hairpins of poxviruses have been difficult to clone and sequence, hence, it is not surprising that some of the published genome sequences (e.g., VACV, ACAM 2000 and HPXV MNR-76) are incomplete.
  • the published sequence of the HPXV genome is likewise incomplete, probably missing ⁇ 60 bp from the terminal ends.
  • the HPXV hairpins cannot be precisely replicated.
  • 129 nt ssDNA fragments were chemically synthesized using the published sequence of the VACV terminal hairpins as a guide and ligated onto dsDNA fragments comprising left and right ends of the HPXV genome.
  • ssDNA fragments were chemically synthesized using the published sequence of the wtVACV WR strain terminal hairpin loops as a guide and ligated onto dsDNA fragments comprising left and right ends of the VACV strain NYCBH.
  • the viral genome of the scPV of the present disclosure comprises homologous or heterologous terminal hairpin loops and the tandem repeat regions (the 70 bp, the 125 bp and the 54 bp tandem repeats) located downstream of the hairpin loops, wherein the tandem repeat regions comprise a different number of repeats than the wtVACV (i.e. the virus present in nature).
  • the number of repeats of the 70 bp, the 125 bp and the 54 bp tandem repeats found in the VACV virus, strain WR were 22, 2 and 8, respectively.
  • the number of tandem repeat regions are variable in the different poxviruses, in the different vaccinia viruses or in the different vaccinia virus strains.
  • the term“homologous terminal hairpin loops” means that said terminal hairpin loops are coming from the same virus species/ the same strain, while the term“heterologous terminal hairpin loops” means that said terminal hairpin loops are coming from a different virus species/ different strain.
  • the terminal hairpins of an scPV of the invention are derived from VACV.
  • the terminal hairpins are derived from CMLV, CPXV, ECTV, HPXV, MPXV, RPXV, raccoonpox virus, skunkpox virus, Taterapox virus, Uasin Gishu disease virus or VPV.
  • the terminal hairpin loops are based on a strain selected from the group of: Western Reserve, Clone 3, Tian Tian, Tian Tian clone TP5, Tian Tian clone TP3, NYCBH, NYCBH clone Acambis 2000, Wyeth, Copenhagen, Lister, Lister 107, Lister-LO, Lister GL-ONC1, Lister GL-ONC2, Lister GL-ONC3, Lister GL- ONC4, Lister CTC1, Lister IMG2 (Turbo FP635), IHD-W, LCl6ml8, Lederle, Tashkent clone TKT3, Tashkent clone TKT4, USSR, Evans, Praha, L-IVP, V-VET1 or LIVP 6.1.1, Ikeda, EM-63, Malbran, Duke, 3737, CV-l, Connaught Laboratories, Serro 2, CM-01, NYCBH Dryvax clone DPP13, NYCBH
  • the terminal hairpin loops are based on the Western Reserve strain (WR strain) of VACV. In another embodiment, the terminal hairpin loops are based on the ACAM2000 strain. New VACV strains are still being constantly discovered. It is understood that an scPV of the various aspects of the invention may be based on such a newly discovered poxviruses or newly discovered strains.
  • the modifications may include the deletion of one or more restriction sites.
  • the modifications may include the introduction of one or more restriction sites.
  • the restriction sites to be deleted from the genome or added to the genome may be selected from one or more of restriction sites such as but not limited to Aanl, Aar I, A as I, Aatl, Aatll, AbaSI, Absl, Acc65I , Actf, AccII, AccIH, Acil, Acll, A cul, Afel, 4/7/7, AflIII, Agel, A hdl, Alel, Alul, A /it /, AlwNI, Apal, ApaLl, ApeKI, Apol, Ascl, Asel, A si SI, Aval, Avail, A vrll, BaeGI, Bael, BamHI Banl, Banll, Bbsl, BbvCI, Bbvl, Bed, BceAI, Bcgl, Bc
  • any desired restriction site(s) or combination of restriction sites may be inserted into the genome or mutated and/or eliminated from the genome.
  • one or more Aarl sites are deleted from the viral genome.
  • one or more nod sites are deleted from the viral genome.
  • one or more restriction sites are completely eliminated from the genome (e.g., all the Aarl sites in the viral genome may be eliminated).
  • one or more Aval restriction sites are introduced into the viral genome.
  • one or more SM sites are introduced into the viral genome.
  • the one or more modifications may include the incorporation of recombineering targets including, but not limited to, loxP or FRT sites.
  • the modifications may include the introduction of fluorescence markers such as, but not limited to, green fluorescent protein (GFP), enhanced GFP, yellow fluorescent protein (YFP), cyan/blue fluorescent protein (BFP), red fluorescent protein (RFP), or variants thereof, etc.; selectable markers such as but not limited to drug resistance markers (e.g., E.
  • fluorescence markers such as, but not limited to, green fluorescent protein (GFP), enhanced GFP, yellow fluorescent protein (YFP), cyan/blue fluorescent protein (BFP), red fluorescent protein (RFP), or variants thereof, etc.
  • selectable markers such as but not limited to drug resistance markers (e.g., E.
  • coli xanthine-guanine phosphoribosyl transferase gene (gpt), Streptomyces alboniger puromycin acetyltransferase gene (pac ), neomycin phosphotransferase I gene ( nptl ), neomycin phosphotransferase gene II ( nptll ), hygromycin phosphotransferase (hpi), sh hie gene, etc.; protein or peptide tags such as but not limited to MBP (maltose-binding protein), CBD (cellulose-binding domain), GST (glutathione-S-transferase), poly(His), FLAG, V5, c-Myc, HA (hemagglutinin), NE-tag, CAT (chloramphenicol acetyl transferase), DHFR (dihydrofolate reductase), HSV (Herpes simplex virus), VSV-G (Ves
  • the modifications include one or more selectable markers to aid in the selection of reactivated clones (e.g., a fluorescence marker such as YFP, a drug selection marker such as gpt , etc.) to aid in the selection of reactivated viral clones.
  • the one or more selectable markers are deleted from the reactivated clones after the selection step.
  • the invention provides, in some aspects, systems and methods for synthesizing, reactivating and isolating functional synthetic chimeric poxviruses (scPVs) from chemically synthesized overlapping double-stranded DNA fragments of the viral genome. Recombination of overlapping DNA fragments of the viral genome and reactivation of the functional scPV are carried out in cells previously infected with a helper virus. Briefly, overlapping DNA fragments that encompass all or substantially all of the viral genome of the scPV are chemically synthesized and transfected into helper virus-infected cells. The transfected cells are cultured to produce mixed viral progeny comprising the helper virus and reactivated scPV.
  • scPVs functional synthetic chimeric poxviruses
  • the mixed viral progeny are plated on host cells that do not support the growth of the helper virus but allow the synthetic chimeric poxvirus to grow, in order to eliminate the helper virus and recover the synthetic chimeric poxvirus.
  • the helper virus does not infect the host cells.
  • the helper virus can infect the host cells but grows poorly in the host cells.
  • the helper virus grows more slowly in the host cells compared to the scPV.
  • substantially all of the synthetic chimeric poxvirus genome is derived from chemically synthesized DNA. In some embodiments, about 40%, about 50%, about 60%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, over 99%, or 100% of the synthetic chimeric vaccinia virus genome is derived from chemically synthesized DNA. In some embodiments, the poxvirus genome is derived from a combination of chemically synthesized DNA and naturally occurring DNA. In some embodiments, all of the fragments encompassing the vaccinia virus genome are chemically synthesized. In some embodiments, one or more of the fragments are chemically synthesized and one or more of the fragments are derived from naturally occurring DNA (e.g., by PCR amplification or by well-established recombinant DNA techniques).
  • the number of overlapping DNA fragments used in the various embodiments of the methods of the invention will depend on the size of the poxvirus genome, such as horsepox virus or vaccinia virus. Practical considerations such as reduction in recombination efficiency as the number of fragments increases on the one hand, and difficulties in synthesizing very large DNA fragments as the number of fragments decreases on the other hand, will also inform the number of overlapping fragments used in the methods of the invention.
  • the synthetic chimeric vaccinia virus genome may be synthesized as a single fragment.
  • the synthetic chimeric vaccinia virus genome is assembled from 2-14 overlapping DNA fragments.
  • the synthetic chimeric vaccinia virus genome is assembled from 4-12 overlapping DNA fragments. In some embodiments, the synthetic chimeric vaccinia virus genome is assembled from 6-12 overlapping DNA fragments. In some embodiments, the synthetic chimeric vaccinia virus genome is assembled from 8-11 overlapping DNA fragments. In some embodiments, the synthetic chimeric vaccinia virus genome is assembled from 8-10, 10-12, or 10-14 overlapping DNA fragments. In some embodiments, the synthetic chimeric vaccinia virus genome is assembled from 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 overlapping DNA fragments. In an exemplary embodiment, the synthetic chimeric vaccinia virus genome is assembled from 9 overlapping DNA fragments.
  • the synthetic chimeric horsepox virus genome is assembled from 2-14 overlapping DNA fragments. In some embodiments, the synthetic chimeric horsepox virus genome is assembled from 4-12 overlapping DNA fragments. In some embodiments, the synthetic chimeric horsepox virus genome is assembled from 6-12 overlapping DNA fragments. In some embodiments, the synthetic chimeric horsepox virus genome is assembled from 8-11 overlapping DNA fragments. In some embodiments, the synthetic chimeric horsepox virus genome is assembled from 8-10, 10-12, or 10-14 overlapping DNA fragments. In some embodiments, the synthetic chimeric horsepox virus genome is assembled from 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 overlapping DNA fragments.
  • a synthetic vaccinia virus (scYACY) is reactivated from 9 chemically synthesized overlapping double-stranded DNA fragments.
  • a synthetic chimeric horsepox virus (scHPXV) is reactivated from 10 chemically synthesized overlapping double-stranded DNA fragments.
  • terminal hairpin loops are synthesized separately and ligated onto the fragments comprising the left and right ends of the vaccinia virus genome.
  • terminal hairpin loops may be derived from a naturally occurring template.
  • the terminal hairpins of an scPV of the disclosure are derived from VACV.
  • the terminal hairpins are derived from CMLV, CPXV, ECTV, HPXV, MPXV, RPXV, raccoonpox virus, skunkpox virus, Taterapox virus, Uasin Gishu disease virus or VPV.
  • the terminal hairpins of an scVACV of the invention are derived from wtVACV.
  • the terminal hairpins are derived from wtVACV terminal hairpins of a different strain in lieu of the VACV own terminal hairpin loop sequences.
  • the terminal hairpins are based on the terminal hairpins of any wtVACV whose genome has been completely sequenced or a natural isolate of which is available for genome sequencing.
  • the terminal hairpins are derived from VACV.
  • the size of the overlapping fragments used in the various embodiments of the methods of the invention will depend on the size of the poxvirus genome. It is understood that there can be wide variations in fragment sizes and various practical considerations, such as the ability to chemically synthesize very large DNA fragments, will inform the choice of fragment sizes.
  • the fragments range in size from about 2,000 bp to about 50,000 bp. In some embodiments, the fragments range in size from about 3,000 bp to about 45,000 bp. In some embodiments, the fragments range in size from about 4,000 bp to 40,000 bp. In some embodiments, the fragments range in size from about 5,000 bp to 35,000 bp.
  • the largest fragments are about 18,000 bp, 20,000 bp, 21,000 bp, 22,000 bp, 23,000 bp, 24, 000 bp, 25,000 bp, 26,000 bp, 27,000 bp, 28,000 bp, 29,000 bp, 30,000 bp, 31,000 bp, 32,000 bp, 33,000 bp, 34,000 bp, 35,000 bp, 36,000 bp, 37,000 bp, 38,000 bp, 39,000 bp, 40,000 bp, 41,000 bp, 42,000 bp, 43,000 bp, 44,000 bp, 45,000 bp, 46,000 bp, 47,000 bp, 48,000 bp, 49,000 bp, or 50,000 bp.
  • an scVACV is reactivated from 9 chemically synthesized overlapping double-stranded DNA fragments ranging in size from about 10,000 bp to about 32,000 bp (Table 4).
  • an scHPXV is reactivated from 9 chemically synthesized overlapping double-stranded DNA fragments ranging in size from about 10,000 bp to about 32,000 bp (Table 1).
  • the helper virus may be any poxvirus that can provide the trans-acting enzymatic machinery needed to reactivate a poxvirus from transfected DNA.
  • the helper virus may have a different or narrower host cell range than an scPV to be produced (e.g., Shope fibroma virus (SFV) has a very narrow host range compared to Orthopoxviruses such as vaccinia virus (VACV) or HPXV).
  • the helper virus may have a different plaque phenotype compared to the scPV to be produced.
  • the helper virus is a Leporipoxvirus .
  • the Leporipoxvirus is an SFV, hare fibroma virus, rabbit fibroma virus, squirrel fibroma virus, or myxoma virus.
  • the helper virus is an SFV.
  • the helper virus is an Orthopoxvirus.
  • the Orthopoxvirus is a camelpox virus (CMLV), cowpox virus (CPXV), ectromelia virus (ECTV, “mousepox agent”), HPXV, monkeypox virus (MPXV), rabbitpox virus (RPXV), raccoonpox virus, skunkpox virus, Taterapox virus, Uasin Gishu disease virus, VACV and volepox virus (VPV).
  • the helper virus is an Avipoxvirus, Capripoxvirus, Cervidpoxvirus, Crocodylipoxvirus, Molluscipoxvirus , Parapoxvirus, Suipoxvirus , or Yatapoxvirus.
  • the helper virus is a fowlpox virus. In some embodiments, the helper virus is an Alphaentomopoxvirus , Betaentomopoxvirus, or Gammaentomopoxvirus . In some embodiments, the helper virus is a psoralen-inactivated helper virus. In an exemplary embodiment of the disclosure, an scPV is reactivated from overlapping DNA fragments transfected into SFV-infected BGMK cells. The SFV is then eliminated by plating the mixed viral progeny on BSC-40 cells.
  • the helper virus is a Leporipoxvirus and the host cells used for the reactivation step may be selected from rabbit kidney cells (e.g., LLC-RK1, RK13, etc.), rabbit lung cells (e.g., R9ab), rabbit skin cells (e.g., SFlEp, DRS, RAB-9), rabbit cornea cells (e.g., SIRC), rabbit carcinoma cells (e.g., Oc4T/cc), rabbit skin/carcinoma cells (e.g., CTPS), monkey cells (e.g., Vero, BGMK, etc.) or hamster cells (e.g., BHK-21, etc.).
  • the helper virus is SFV.
  • the scPVs of the present invention can be propagated in any substrate that allows the virus to grow to titers that permit the uses of the scPVs described herein.
  • the substrate allows the scPVs to grow to titers comparable to those determined for the corresponding wild-type viruses.
  • the scPVs may be grown in cells (e.g., avian cells, bat cells, bovine cells, camel cells, canary cells, cat cells, deer cells, equine cells, fowl cells, gerbil cells, goat cells, human cells, monkey cells, pig cells, rabbit cells, raccoon cells, seal cells, sheep cells, skunk cells, vole cells, etc.) that are susceptible to infection by the poxviruses.
  • cells e.g., avian cells, bat cells, bovine cells, camel cells, canary cells, cat cells, deer cells, equine cells, fowl cells, gerbil cells, goat cells, human cells, monkey cells, pig cells, rabbit cells, raccoon cells, seal cells, sheep cells, skunk cells, vole cells, etc.
  • cells e.g., avian cells, bat cells, bovine cells, camel cells, canary cells, cat cells, deer cells, equine cells, fowl cells,
  • Representative mammalian cells include, but are not limited to BHK, BGMK, BRL3A, BSC- 40, CEF, CEK, CHO, COS, CVI, HaCaT, HEL, HeLa cells, HEK293, human bone osteosarcoma cell line 143B, MDCK, NIH/3T3, Vero cells, etc.).
  • the scPV is removed from cell culture and separated from cellular components, typically by well-known clarification procedures, e.g., such as gradient centrifugation and column chromatography, and may be further purified as desired using procedures well known to those skilled in the art, e.g., plaque assays.
  • the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising the isolated stem cell or population thereof of the invention and a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable means approved by a regulatory agency of the Federal or a state government or listed in the ET.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
  • carrier refers to a diluent, adjuvant, excipient, or vehicle with which the pharmaceutical composition (e.g., immunogenic or vaccine formulation) is administered.
  • Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions.
  • Suitable excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.
  • suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences” by E. W. Martin. The formulation should suit the mode of administration.
  • the pharmaceutical composition of the invention may be administered by standard routes of administration. Many methods may be used to introduce the formulations into a subject, these include, but are not limited to, intranasal, intratracheal, oral, intradermal, intramuscular, intraperitoneal, intravenous, conjunctival and subcutaneous routes.
  • the invention relates to a method for delivery of a synthetic chimeric poxvirus (scPV) into a subject, the method comprising infecting the stem cells of the invention with a synthetic chimeric poxvirus and administering the scPV-infected stem cells into the subject.
  • scPV synthetic chimeric poxvirus
  • Methods to infect the stem cells of the invention with a synthetic chimeric poxvirus are known in the art. Those skilled in the art can determine appropriate parameters, such as number of stem cells and multiplicity of infection.
  • the stem cells are autologous and the invention relates to a method for delivery of a scPV into a subject, the method comprising (a) obtaining the stem cells from said subject; (b) infecting the stem cells with the oncolytic scPV and (c) administer the scPV infected stem cells back into the subject.
  • the stem cells are mesenchymal stem cells (MSC).
  • MSC mesenchymal stem cells
  • the MSC derive from the subject’s adipose tissue.
  • the stem cells are allogeneic and the invention relates to a method for delivery of a scPV into a subject, the method comprising (a) obtaining the stem cells from a subject; (b) infecting the stem cells with the oncolytic scPV and (c) administer the scPV infected stem cells back into the subject.
  • the stem cells of the invention are administered in a single administration or in multiple administrations.
  • the stem cells can be implanted locally at the site of cell damage or dysfunction, or systemically.
  • routes of administration of the stem cell compositions include, but are not limited to, intravenous, intramuscular, intradermal, intraperitonal, intracoronary, intramyocardial, transendocardial, trans-epicardial, intraspinal, intra-arterial, intra-striatum, intratumoral, topical, transdermal, rectal or sub-epidermal routes.
  • the most suitable route for administration will vary depending upon the disorder or condition to be treated, such as the location of cell damage or dysfunction.
  • stem cells can be administered intra- arterially or intra-spinally at the site of injury for the treatment of spinal cord injury.
  • stem cell compositions can be administered by an intracoronary, intramyocardial, transendocardial or trans-epicardial route for the treatment of cardiovascular disease.
  • the administration is intravenously.
  • the amount of scPV used for the stem cells infection is 1 x 10 5 or about 1 x 10 5 plaque forming units (PFU), 5 x 10 5 or about 5 x 10 5 PFU, at least 1 x 10 6 or about 1 x 10 6 PFU, 5 x 10 6 or about 5 x 10 6 PFU, 1 x 10 7 or about 1 x 10 7 PFU, 5 x 10 7 or about 5 x 10 7 PFU, 1 x 10 8 or about 1 x 10 8 PFU, 5 x 10 8 or about 5 x 10 8 PFU, 1 x 10 9 or about 1 x 10 9 PFU, 5 x 10 9 or about 5 x 10 9 PFU, 1 x 10 10 or about 1 x 10 10 PFU or 5 x 10 10 or about 5 x 10 10 PFU.
  • PFU plaque forming units
  • the multiplicity of infection of scPV used for the stem cells infection is about 0.5 PFU/cell, or about 1 PFU/cell, or about 2 PFU/cell, or about 3 PFU/cell, or about 4 PFU/cell, or about 5 PFU/cell, or about 6 PFU/cell, or about 7 PFU/cell, or about 8 PFU/cell, or about 9 PFU/cell or about 10 PFU/cell.
  • Conditions amenable to stem cell therapy include any in which one or more cell populations are defective or have been depleted or destroyed. Such conditions include degenerative disorders or conditions and acute or chronic injuries. Once the stem cells are implanted or engrafted into the patient, such as at the location of cell or tissue damage or dysfunction, the stem cells can differentiate into the desired cell or tissue type based on the physical and chemical signals in the local extracellular microenvironment, thereby replacing the destroyed or defective cells with functional healthy cells.
  • Exemplary conditions include, but are not limited to, cancer, cardiovascular disease, diabetes, spinal cord injury, neurodegenerative disease, traumatic brain injury, Alzheimer's disease, Parkinson's disease, multiple sclerosis (MS), Amyotrophic lateral sclerosis (ALS), Duchenne Muscular Dystrophy, muscle damage or dystrophy, stroke, bums, lung disease, retinal disease, kidney disease, osteoarthritis, and rheumatoid arthritis.
  • a method for treating or preventing cancer means that any of the symptoms, such as the tumor, metastasis thereof, the vascularization of the tumors or other parameters by which the disease is characterized are reduced, ameliorated, prevented, placed in a state of remission, or maintained in a state of remission. It also means that the indications of cancer and metastasis can be eliminated, reduced or prevented by the treatment. Non limiting examples of the indications include uncontrolled degradation of the basement membrane and proximal extracellular matrix, migration, division, and organization of the endothelial cells into new functioning capillaries, and the persistence of such functioning capillaries.
  • the synthetic chimeric poxviruses (scPVs) of the various aspects of the invention can be used as oncolytic agents that selectively replicate in and kill cancer cells.
  • Cells that are dividing rapidly, such as cancer cells are generally more permissive for poxviral infection than non-dividing cells.
  • Many features of poxviruses, such as safety in humans, ease of production of high-titer stocks, stability of viral preparations, and capacity to induce antitumor immunity following replication in tumor cells make poxviruses desirable oncolytic agents.
  • the scPVs produced according to the methods of the invention may comprise one or modifications that render them suitable for the treatment of cancer.
  • the disclosure provides a method of inducing death in cancer cells, the method comprising contacting the cancer cells with an isolated scPV or pharmaceutical composition comprising an scPV of the invention or the stem cells of the invention.
  • the disclosure provides a method of treating cancer, the method comprising administering to a patient in need thereof, a therapeutically effective amount of the stem cells of the invention or the pharmaceutical composition of the invention.
  • Another aspect includes the use of the stem cells of the invention or the pharmaceutical composition described herein to induce death in a neoplastic disorder cell such as a cancer cell or to treat a neoplastic disorder such as cancer.
  • the poxvirus oncolytic therapy is administered in combination with one or more conventional cancer therapies (e.g., surgery, chemotherapy, radiotherapy, thermotherapy, and biological/immunological therapy).
  • the oncolytic virus is a synthetic chimeric VACV (scVACV) of this invention.
  • the oncolytic virus is a synthetic chimeric myxoma virus of this invention.
  • the oncolytic virus is a synthetic chimeric HPXV (scHPXV) of this invention.
  • the oncolytic virus is a synthetic chimeric raccoonpox virus of this invention.
  • the oncolytic virus is a synthetic chimeric yaba-like disease virus of this invention.
  • the scPVs of the invention for use as oncolytic agents are designed to express transgenes to enhance their immunoreactivity, antitumor targeting and/or potency, cell-to-cell spread and/or cancer specificity.
  • an scPV of the invention is designed or engineered to express an immunomodulatory gene (e.g., GM-CSF, or a viral gene that blocks TNF function).
  • an scPV of the disclosure is designed to include a gene that expresses a factor that attenuates virulence.
  • an scPV of the invention is designed or engineered to express a therapeutic agent (e.g., hEPO, BMP-4, antibodies to specific tumor antigens or portions thereof, etc.).
  • the scPVs of the invention have been modified for attenuation.
  • the scPV of the invention is designed or engineered to lack the viral TK gene.
  • an scVACV of the invention is designed or engineered to lack vaccinia growth factor gene.
  • an scVACV of the invention is designed or engineered to lack the hemagglutinin gene.
  • the stem cells of the various embodiments of the invention are useful for treating a variety of neoplastic disorders and/or cancers.
  • the type of cancer includes but is not limited to bone cancer, breast cancer, bladder cancer, cervical cancer, colorectal cancer, esophageal cancer, gliomas, gastric cancer, gastrointestinal cancer, head and neck cancer, hepatic cancer such as hepatocellular carcinoma, leukemia, lung cancer, lymphomas, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, skin cancer such as melanoma, testicular cancer, etc. or any other tumors or pre-neoplastic lesions that may be treated.
  • the method further comprises detecting the presence of the administered scPV, in the neoplastic disorder or cancer cell and/or in a sample from a subject administered an isolated or recombinant virus or composition described herein.
  • the subject can be tested prior to administration and/or following administration of the scPV or composition described herein to assess for example the progression of the infection.
  • an scPV of the disclosure comprises a detection cassette and detecting the presence of the administered chimeric poxvirus comprises detecting the detection cassette encoded protein.
  • the detection cassette encodes a fluorescent protein
  • the subject or sample is imaged using a method for visualizing fluorescence.
  • the stem cells of the various embodiments of the invention are administered in a single administration or in multiple administrations.
  • the stem cells of the invention can be implanted locally at the site of cell damage or dysfunction, or systemically in order to be used in a method to treat cancer.
  • routes of administration of the stem cell compositions include, but are not limited to, intravenous, intramuscular, intradermal, intraperitonal, intracoronary, intramyocardial, transendocardial, trans-epicardial, intraspinal, intra-arterial, intra-striatum, intratumoral, topical, transdermal, rectal or sub-epidermal routes.
  • the most suitable route for administration will vary depending upon the disorder or condition to be treated, such as the location of cell damage or dysfunction.
  • stem cells can be administered intra- arterially or intra-spinally at the site of injury for the treatment of spinal cord injury.
  • stem cell compositions can be administered by an intracoronary, intramyocardial, transendocardial or trans-epicardial route for the treatment of cardiovascular disease.
  • the administration is intravenously.
  • the scPV for use in a method of treatment of cancer can encode a therapeutic gene product.
  • the therapeutic gene product is an anti-cancer agent or anti- angiogenic agent.
  • the therapeutic gene product can be selected from among a cytokine, a chemokine, an immunomodulatory molecule, an antigen, an antibody or fragment thereof, an antisense RNA, a prodrug converting enzyme, an siRNA, an angiogenesis inhibitor, a toxin, an antitumor oligopeptide, a mitosis inhibitor protein, an antimitotic oligopeptide, an anti-cancer polypeptide antibiotic, a transporter protein, and a tissue factor.
  • the method for treatment of cancer including the stem cells of the invention can also include administering an anticancer agent.
  • anticancer agents include, but are not limited to, a cytokine, a chemokine, a growth factor, a photosensitizing agent, a toxin, an anti cancer antibiotic, a chemotherapeutic compound, a radionuclide, an angiogenesis inhibitor, a signaling modulator, an antimetabolite, an anti-cancer vaccine, an anti-cancer oligopeptide, a mitosis inhibitor protein, an antimitotic oligopeptide, an anti-cancer antibody, an anti-cancer antibiotic, an immunotherapeutic agent, hyperthermia or hyperthermia therapy, a bacterium, radiation therapy and a combination of such agents.
  • the anticancer agent is cisplatin, carboplatin, gemcitabine, irinotecan, an anti-EGFR antibody, or an anti-VEGF antibody. In some examples, the anticancer agent is administered simultaneously, sequentially, or intermittently with the virus.
  • the method can also include administering an anti-viral agent to attenuate replication of or eliminate the virus from the subject during or following therapy.
  • antiviral agents include, but are not limited to, cidofovir, alkoxyalkyl esters of cidofovir, Gleevec, gancyclovir, acyclovir and ST-26.
  • the scPV contains a gene deletion.
  • a gene deletion is understood to be the loss or absence of a DNA sequence of a gene, or a deficiency in that gene or a deletion mutation, in which part of a chromosome or a sequence of DNA is lost during DNA replication.
  • the deleted gene is selected from a gene encoding a protein or fragment thereof, a gene segment that regulates transcription, a gene segment that regulates viral replication, a gene segment that affects cellular mitosis, a gene segment that affects cellular metabolism, a gene segment that encodes an antisense RNA, a gene segment that encodes an siRNA, a gene segment that regulates angiogenesis, a gene segment that regulates one or more transporter proteins, or a gene segment that regulates one or more tissue factors.
  • the gene deletion potentiates the anti-cancer or the anti-angiogenic effect of the virus.
  • the term“potentiates the effect”, as used herein, means that the anti-cancer or the anti-angiogenic compounds are more effective or more active after the gene deletion, which means that the activity of the compounds is augmented after the gene deletion was performed on the scPV.
  • the stem cells of the various aspects of the invention can be used to treat a variola virus infection.
  • treatment refers to the eradication or control of the replication of an infectious agent (e.g., the poxvirus or the variola virus), the reduction in the numbers of an infectious agent (e.g., the reduction in the titer of the virus), the reduction or amelioration of the progression, severity, and/or duration of an infection (e.g., a poxviral/ variola infection or a condition or symptoms associated therewith), or the amelioration of one or more symptoms resulting from the administration of one or more therapies (including, but not limited to, the administration of one or more prophylactic or therapeutic agents).
  • an infectious agent e.g., the poxvirus or the variola virus
  • the reduction in the numbers of an infectious agent e.g., the reduction in the titer of the virus
  • the reduction or amelioration of the progression, severity, and/or duration of an infection e.g., a poxviral/
  • the stem cells of the invention are administered in a single administration or in multiple administrations for the treatment of a variola infection.
  • routes of administration of the stem cell compositions include, but are not limited to, intravenous, intramuscular, intradermal, intraperitonal, intracoronary, intramyocardial, transendocardial, trans-epicardial, intraspinal, intra-arterial, intra-striatum, intratumoral, topical, transdermal, rectal or sub-epidermal routes.
  • TTTATTAAATTTTACTATTTATTTAGTGTCTAGAAAAAAA-3’ was not included in the synthesized inverted terminal repeat (ITR) fragments. Instead, a Sapl restriction site was added at the 5’ -terminus (GA LITR) and 3’ -terminus (GA RITR) of the ITR fragments followed by a TGT sequence. These Sapl restriction sites were used to ligate the VACV terminal hairpins onto the ITR fragments (described below).
  • Each fragment was chemically synthesized and subcloned into a plasmid using terminal Sfil restriction sites on each fragment. To assist with sub-cloning these fragments, Aarl and Bsal restriction sites were silently mutated in all the fragments, except for the two ITR-encoding fragments (Table 2). The Bsal restriction sites in the two ITR-encoding fragments were not mutated, in case these regions contained nucleotide sequence-specific recognition sites that were important for efficient DNA replication and concatemer resolution.
  • a yfp/gpt cassette under the control of a poxvirus early late promoter was introduced into the HPXV095/J2R locus within GA_Fragment_3) so that reactivation of HPXV (scHPXV YFP-gpt: :095) was easy to visualize under a fluorescence microscope.
  • the gpt locus also provided a potential tool for selecting reactivated viruses using drug selection.
  • HPXV095 encodes the HPXV homolog of the non-essential VACV J2R gene and by co-transfecting Fragment_3 and other HPXV clones into SFV-infected BGMK cells, along with VACV DNA, a variety of hybrid viruses were recovered, validating the selection strategy (Fig. 10A and 10B).
  • Silent mutations were also introduced into the HPXV044 (VACV WR F4L) sequence (GA_Fragment_2) to create two unique restrictions sites within GA_Fragment_2 (Table 3). In some embodiments, these unique restriction sites may be used to rapidly introduce recombinant gene products (such as but not limited to, selectable markers, fluorescent proteins, antigens, etc.) into GA_Fragment_2 prior to reactivation of HPXV.
  • Table 1 The HPXV genome fragments used in this study. The size of each fragment and location within the HPXV genome are indicated.
  • Table 3 Introduction of silent nucleotide mutations in the HPXV044 (VACV F4L) gene to create unique restriction endonuclease sites in GA_Fragment_2.
  • ITR fragments were individually digested with Sapl (ThermoFisher Scientific) for 1 h, inactivated at 65°C for 10 minutes, before digestion with Sfil overnight at 50°C. Approximately 1U of FastAP alkaline phosphatase was added to the scHPXV YFP-gpt::095 ITR digestions and incubated at 37°C for an additional 1 h. All scHPXV YFP-gpt: :095 fragments were subsequently purified using a QiaexII DNA cleanup kit (Qiagen).
  • Sapl ThermoFisher Scientific
  • Poxviruses catalyze very high-frequency homologous recombination reactions that are inextricably linked to the process of virus replication.
  • large fragments of chemically synthesized HPXV duplex DNA can be joined to form a functional scHPXV genome using virus-catalyzed recombination and replication reactions.
  • these plasmids were digested with Sfil to release the plasmid from each scHPXV YFP- gpt: :095 fragment (see below for how the LITR and RITR fragments are processed). Following digestion, each reaction was purified to remove any contaminating enzyme, but the plasmid was not removed from the digestion and was co-transfected alongside each scHPXV YFP- gpt: :095 fragment. This did not interfere with the reaction and was done to minimize the amount of DNA manipulation and possible fragmentation of these large DNA fragments.
  • reaction efficiency may be affected by the number of transfected fragments, greater than or less than 10 overlapping fragments may be used in the methods of the disclosure.
  • -15 fragments may represent a practical upper limit without further optimization of the reactivation reaction.
  • the ideal lower limit would be a single genome fragment, but in practice the telomeres are most easily manipulated as more modest sized fragments (e.g., -10 kb).
  • VACV F- and S-terminal hairpin loops onto scHPXV YFP-gpt::095 left and right ITR fragments [0133] Approximately one microgram of each of the terminal VACV hairpin loops was incubated at 95 °C for 5 minutes followed by a“snap” cool on ice to form the hairpin structure. The hairpin loops were subsequently phosphorylated at their 5’ end before ligation.
  • Orthopoxviruses encode linear dsDNA genomes bearing variable length inverted terminal repeats (ITR) at each end of the genome.
  • the two strands of the duplex genome are connected by hairpin loops to form a covalently continuous polynucleotide chain.
  • the loops are A+T-rich, cannot form a completely base-paired structure, and exist in two forms that are inverted and complementary in sequence (Baroudy BM, Venkatesan S, Moss B). Incompletely base-paired flip-flop terminal loops link the two DNA strands of the vaccinia virus genome into one uninterrupted polynucleotide chain. Cell. 1982;28(2):315-24) (Fig. 2B).
  • BGMK Buffalo green monkey kidney
  • MEM minimal essential medium
  • FCS fetal calf serum
  • BGMK Buffalo green monkey kidney
  • Lipofectamine complexes were prepared by mixing approximately 5 pg total synthetic HPXV DNA fragments in lml Opti-MEM with Lipofectamine2000 diluted in lml Opti-MEM at a ratio of 3 : 1 (Lipofectamine2000 to total DNA). The complexes were incubated at room temperature for 10 minutes and then added dropwise to the BGMK cells previously infected with SFV. Approximately l6h post infection, the media was replaced with fresh MEM containing 5% FCS. The cells were cultured for an additional 4d (total of 5d) at 37°C. Virus particles were recovered by scraping the infected cells into the cell culture medium and performing three cycles of freezing and thawing.
  • the crude extract was diluted 10 2 in serum- free MEM and 4ml of the inoculum was plated on 9 - 16 l50mm tissue culture plates of BSC- 40 cells to recover reactivated scHPXV YFP-gpt: :095.
  • MEM containing 5% FCS and 0.9% Noble Agar.
  • Yellow fluorescent plaques were visualized under an inverted microscope and individual plaques were picked for further analysis. ScHPXV YFP-gpt: :095 plaques were plaque purified three times with yellow fluorescence selection.
  • SFV has a narrow host range, productively infecting rabbit cells and certain monkey cell lines, like BGMK. It can infect, but grows very poorly on cells like BSC-40.
  • helper viruses such as but not limited to fowlpox virus
  • helper viruses may be used.
  • different cell combinations may be used.
  • BGMK cells were infected with SFV at a MOI of 0.5 and then transfected with 5pg of digested GA HPXV fragments 2 h later. Five days post transfection all of the infectious particles were recovered by cell lysis and re-plated on BSC-40 cells, which only efficiently supported growth of HPXV (or other Orthopoxviruses). The resulting reactivated scHPXV YFP-gpt: :095 plaques were visualized under a fluorescence microscope.
  • the visualization was enabled by the yfp/gpt selectable marker in the HPXV095/J2R locus within Frag_3 (Fig. 2A). Virus plaques were detected in BSC-40 monolayers within 48 h of transfection. The efficiency of recovering scHPXV YFP-gpt: :095 was dependent on a number of factors, including DNA transfection efficiency, but ranged up to a few PFU/pg of DNA transfected.
  • Digested DNA was run on a 1% Seakem Gold agarose gel cast and run in 0.5X tris-borate-EDTA electrophoresis (TBE) buffer [1 lOmM tris; 90mM borate; 2.5mM EDTA]
  • TBE 0.5X tris-borate-EDTA electrophoresis
  • the DNA was resolved on a CHEF DR-III apparatus (BioRad) at 5.7V/cm for 9.5h at l4°C, using a switching time gradient of 1 to lOs, a linear ramping factor, and a 120° angle. This program allows resolution of DNA species from lkbp to >200kbp.
  • each reaction was digested with Bsal and the resulting DNA fragments were analyzed by gel electrophoresis. Since no Bsal sites were mutated in VACV (wt), enzymatic digestion successfully digested each PCR product, resulting in a smaller DNA fragment.
  • the PCR products generated from scHPXV YFP-gpt: :095 genomic DNA were resistant to Bsal digestion, suggesting that the Bsal recognition site was successfully mutated in these genomes.
  • primer products for primer set 7C did not result in any amplification of DNA in the scHPXV YFP-gpt: :095 PP1 and PP3 samples.
  • PCR was performed on the original GA_Frag_7 plasmid DNA and this reaction was also unsuccessful in amplifying a product.
  • Genomic DNA was next isolated from sucrose-gradient purified scHPXV YFP- gpt: :095 genomes, digested with fNal or Hindlll, and separated by agarose gel electrophoresis to confirm that the majority of the Bsal sites in scHPXV YFP-gpt: :095 are successfully mutated.
  • HPXV095 encodes the HPXV homolog of the non-essential VACV J2R gene
  • co-transfecting Fragment_3 and other HPXV clones into SFV-infected BGMK cells along with VACV DNA
  • the first hybrid virus (“VACV/HPXV + fragment 3”) was obtained by co-transfecting VACV DNA with HPXV Frag_3 into SFV-infected cells.
  • the green-tagged insertion encodes the YFP-gpt selection marker.
  • Clones 1-3 were obtained by purifying the DNA from this first hybrid genome and transfecting it again, along with HPXV fragments 2, 4, 5, and 7, into SFV-infected cells. PCR primers were designed to target both HPXV and
  • VACV (Table 5) were used to amplify DNA segments spanning the Bsal sites that were mutated in the scHPXV clones. Following PCR amplification, the products were digested with Bsal to differentiate VACV sequences (which cut) from HPXV (which do not cut). The VACV/HPXV hybrids exhibited a mix of Bsal sensitive and resistant sites whereas the reactivated scHPXV YFP-gpt: :095 clone was fully Bsal resistant.
  • scHPXV YFP-gpt :095 genomes were sequenced using a multiplex approach and an Illumina MiSeq sequencer. The sequence reads were mapped onto the wild-type HPXV (DQ792504) and scHPXV YFP-gpt: :095 reference sequences to confirm the presence of specific modifications in the scHPXV YFP-gpt: :095 genome. To confirm that the VACV terminal repeat sequences were correctly ligated onto the terminal end of the left ITR, sequencing reads in this area of the genome were analyzed.
  • a string of Cs was added to the beginning of the scHPXV YFP-gpt: :095 genome reference sequence to capture all of the sequence reads that mapped in this region. This was done because the program used to assemble the sequence reads will otherwise truncate the display of sequences at the point where the scHPXV YFP-gpt: :095 genome reference sequence ends.
  • BSC-40, HeLa, and HEL fibroblasts were originally obtained from the American
  • BSC-40 cells are propagated at 37°C in 5% C0 2 in minimal essential medium (MEM) supplemented with L-glutamine, nonessential amino acids, sodium pyruvate, antibiotics and antimycotics, and 5% fetal calf serum (FCS; ThermoFisher Scientific).
  • MEM minimal essential medium
  • FCS fetal calf serum
  • HeLa and HEL cells were propagated at 37°C in 5% C0 2 in Dulbecco’s modified Eagle’s medium supplemented with L-glutamine, antibiotics and antimycotics, and 10% FCS.
  • Multi-step growth curves and plaque size measurements were used to evaluate whether scHPXV YFP-gpt: :095 replicated and spread in vitro similar to other Orthopoxviruses. Since a natural HPXV isolate was unavailable, the growth of scHPXV YFP-gpt: :095 was compared to the prototypic poxvirus, VACV (strain WR), Cowpox virus (CPX), a poxvirus that was closely related to HPXV and a clone of Dryvax virus, DPP15.
  • VACV strain WR
  • CPX Cowpox virus
  • DPP15 clone of Dryvax virus
  • BSC-40 Monkey kidney epithelial cells
  • Vero cells a human carcinoma cell line (HeLa)
  • HEL primary human fibroblasts cells
  • plaque size of scHPXV YFP-gpt: :095 grown in BSC-40 cells was measured.
  • a statistically significant decrease in plaque size of scHPXV YFP-gpt: :095 compared to VACV WR and even cowpox virus (Fig. 6B) was observed.
  • scHPXV YFP-gpt: :095 produced the smallest plaques when compared to all other Orthopoxviruses tested (Fig. 6C).
  • different VACV strains produced extracellular viruses that form smaller secondary plaques, these were not produced by scHPXV YFP- gpt: :095 (Fig. 6C).
  • BSC-40 cells were infected with scHPXV YFP-gpt: :095 at a MOI of 0.5 and then transfected, 2 h later, with 2 pg of linearized plasmid containing the wtHPXV095 sequence using Lipofectamine 2000 (ThermoFisher Scientific).
  • the virus recombinants were harvested 48 h post infection and recombinant viruses (scHPXV (wt)) were isolated using three rounds of non-fluorescent plaque purification under agar.
  • PCR was used to confirm the identity of the scHPXV (wt) using primers that flanked the HPXV095 gene locus.
  • the primers used to confirm the correct replacement of the HPXV095 gene are HPXV095_check-FWD 5’- CCTATTAGATACATAGATCCTCGTCG-3’ (SEQ ID NO: 52) and HPXV095_check-REV 5’ -CGGTTT ATCTAACGAC AC AAC ATC-3’ (SEQ ID NO: 53).
  • scHPXV(wt) shows growth properties not significantly different from scHPXV YFP-gpt::095 in vitro (Fig. 11A-C).
  • Fig. 11A-C A statistically significant decrease in plaque size of scHPXV(wt) compared to VACV WR was observed (Fig. 11A).
  • scHPXV (wt) like scHPXV YFP-gpt::095, did not produce extracellular viruses (Fig.
  • scHPXV The toxicity effects of scHPXV (wt) were determined in this study.
  • 6 groups of Balb/c mice were administered 3 different doses of scHPXV (AHPXV 095/J2R) or scHPXV (wt) described in the Examples and compared to a PBS control group as well as a VACV (WR) control group and a VACV (Dryvax strain DPP 15) control group (9 treatment groups in total).
  • VACV WR
  • VACV Dellvax strain DPP 15
  • the scHPXV doses chosen for this study (10 5 PFU/dose, 10 6 PFU/dose, and 10 7 PFU/dose) were based on previous studies using known vaccine strains of VACV, including Dryvax and IOC (Medaglia ML, Moussatche N, Nitsche A, Dabrowski PW, Li Y, Damon IK, et al. Genomic Analysis, Phenotype, and Virulence of the Historical Brazilian Smallpox Vaccine Strain IOC: Implications for the Origins and Evolutionary Relationships of Vaccinia Virus. Journal of Virology. 20l5;89(23): 11909-25; Qin L, Favis N, Famulski J, Evans DH. Evolution of and evolutionary relationships between extant vaccinia virus strains. Journal of Virology. 20l5;89(3): 1809-24).
  • VACV strain WR
  • DPP15 The VACV Dryvax clone, DPP15, was also administered intranasally at 10 7 PFU/dose, so that the virulence of this well-known Smallpox vaccine could be directly compared to scHPXV (wt).
  • Mice were purchased from Charles River Laboratories and once received, were acclimatized to their environment for at least one week prior to virus administration.
  • Each mouse received a single dose of virus ( ⁇ l0ul) administered via the intranasal injection while under anesthesia. Mice were monitored for signs of infection, such as swelling, discharge, or other abnormalities every day for a period of 30 days. Each mouse was specifically monitored for weight loss every day after virus administration. Mice that lose more than 25% of their body weight in addition to other morbidity factors were subjected to euthanasia in accordance with our animal health care facility protocols at the University of Alberta.
  • mice that appeared to have been unaffected by the initial virus administration described in the Example continued to gain weight normally throughout the experiment.
  • Thirty days post virus inoculation mice were subsequently challenged with a lethal dose of VACV- WR (10 6 PFU/dose) via intranasal inoculation. Mice were closely monitored for signs of infection as described above. Mice were weighed daily and mice that lost greater than 25% of their body weight in addition to other morbidity factors were subjected to euthanasia.
  • mice inoculated with PBS prior to administration of a lethal dose of VACV-WR showed signs of significant weight loss and other morbidity factors within 7-10 days post inoculation.
  • Approximately 14 days post lethal challenge with VACV-WR all mice were euthanized and blood was collected to confirm the presence of VACV-specific neutralizing antibodies in the serum by standard plaque reduction assays.
  • the design of the scVACV genome was based on the previously described genome sequence for VACV ACAM2000 [GenBank accession AY313847] (Osborne JD et al. Vaccine. 2007; 25(52):8807-32).
  • the genome was divided into 9 overlapping fragments (Fig. 12). These fragments were designed so that they shared at least 1.0 kbp of overlapping sequence (i.e. homology) with each adjacent fragment, to provide sites where homologous recombination will drive the assembly of full-length genomes (Table 4).
  • These overlapping sequences provided sufficient homology to accurately carry out recombination between the co-transfected fragments (Yao XD, Evans DH. Journal of Virology. 2003;77(l3):728l-90).
  • Table 4 The VACV ACAM2000 genome fragments used in this study. The size and the sequence within the VACV ACAM2000 genome [GenBank Accession AY313847] are described.
  • Aarl and Bsal restriction sites were silently mutated in all the fragments, except for the two ITR-encoding fragments.
  • the Bsal restriction sites in the two ITR-encoding fragments were not mutated, in case these regions contain nucleotide sequence-specific recognition sites that are important for efficient DNA replication and concatamer resolution.
  • a YFP/gpt cassette under the control of a poxvirus early late promoter was introduced into the thymidine kinase locus, so that reactivation of VACV ACAM2000 (VACV ACAM2000 YFP-gpt:: l05) was easy to visualize under a fluorescence microscope.
  • VACV ACAM2000 YFP-gpt:: l05 VACV ACAM2000 YFP-gpt:: l05
  • the gpt locus also provided a potential tool for selecting reactivated viruses using drug selection.
  • VACV ACAM2000 sequence In the published VACV ACAM2000 sequence, however, only four 54bp repeat sequences were identified. The presence of the 70bp, l25bp, and 54bp repeat sequences was confirmed in a wild-type isolate of VACV ACAM2000 after sequencing (using Illumina), indicating that the current published sequence of ACAM2000 is incomplete. Due to the short read lengths of the Illumina reads ( ⁇ 300 nucleotides), the inventors were unable to accurately determine what the actual ACAM2000 genomic sequence was in this ⁇ 3 kbp. Instead, the inventors decided to recreate a VACV ACAM2000 virus that had a similar sequence to VACV WR from the terminal hairpin to just before the stop codon of the C23L gene (Fig 12).
  • Synthetic chimeric VACV ACAM2000 containing VACV ACAM2000 strain hairpin and duplex sequence scVACV ACAM2000-ACAM2000 DUP/HP
  • the design of the scVACV genome was based on the previously described genome sequence for VACV ACAM2000 [GenBank accession AY313847] (Osborne JD et al. Vaccine. 2007; 25(52):8807-32).
  • the genome was divided into 9 overlapping fragments (Fig. 12). These fragments were designed so that they shared at least 1.0 kbp of overlapping sequence (i.e. homology) with each adjacent fragment, to provide sites where homologous recombination will drive the assembly of full-length genomes (Table 4).
  • These overlapping sequences provided sufficient homology to accurately carry out recombination between the co-transfected fragments (Yao XD, Evans DH. Journal of Virology. 2003;77(l3):728l-90).
  • Aarl and Bsal restriction sites were silently mutated in all the fragments, except for the two ITR-encoding fragments.
  • the Bsal restriction sites in the two ITR-encoding fragments were not mutated, in case these regions contain nucleotide sequence-specific recognition sites that are important for efficient DNA replication and concatemer resolution.
  • a YFP/gpt cassette under the control of a poxvirus early late promoter was introduced into the thymidine kinase locus, so that reactivation of VACV ACAM2000 (VACV ACAM2000 YFP-gpt: : l05) was easy to visualize under a fluorescence microscope.
  • the gpt locus also provided a potential tool for selecting reactivated viruses using drug selection.
  • F and S terminal hairpin loop sequences of the wtVACV ACAM2000 are shown in SEQ ID NO: 118 and 117, respectively.
  • a 70bp repeat fragment that was identical to the VACV WR strain was synthesized (Fig. 13A; SEQ ID NO: 63). Sapl and Nhel restriction sites were included at the 5’ and 3’ terminus of the 70bp tandem repeat fragment to facilitate the ligation onto the VACV WR hairpin sequence and the VACV ACAM2000 right and left ITR fragments, respectively.
  • the loop had to be extended an additional 58bp using a duplex sequence synthesized by IDT. This was due to the extra sequence being immediately downstream of the concatemer resolution site, prior to the first 70bp repeat sequence found in VACV strain WR.
  • the duplex sequence was produced by synthesizing two single-stranded DNA molecules that, when annealed together, would produce a duplex DNA molecule with a 5’-TGT overhang at the 5’ end and a 5’-GGT overhang at the 3’ end (SEQ ID NO: 64 and SEQ ID NO: 65). Since the VACV WR F and S terminal hairpin loops generate a 3’-AC A overhang at their terminal loops, the 58bp duplex was ligated to the hairpins to generate an ⁇ l30bp terminal hairpin loop that looked identical to the sequence found in the VACV WR strain up until the beginning of the 70bp repeat sequence.
  • This hairpin/duplex fragment was gel purified and then subsequently ligated onto the Sapl digested end of the 70bp repeat fragment.
  • Digesting the 70bp tandem repeat fragment with Sapl created a three base overhang (5’ -CCA), complementary to the 5’GGT overhang in the terminal hairpin/duplex structure.
  • the 70bp tandem repeat was mixed with either an F terminal hairpin/duplex structure or a S terminal hairpin/duplex structure at a ⁇ 5-fold molar excess relative to the 70bp tandem repeat fragment in the presence of DNA ligase. This produced an upward shift in the DNA electrophoresis gel compared to the 70bp only reaction, indicating that the terminal hairpin/duplex was successfully ligated onto the 70bp tandem repeat fragment.
  • This terminal hairpin/duplex/70bp tandem repeat fragment was subsequently ligated onto the 70bp ACAM2000 left or right ITR fragment that had been previously modified at their terminal ends to include the Nhe ⁇ restriction site.
  • this fragment was digested, a 5’-CTAG overhang was left at their 5’ termini.
  • the Nhel site is used to directly ligate this fragment to the LITR and RITR regions of the VACV ACAM2000 DNA fragments.
  • the S terminal hairpin/duplex/70bp tandem repeat fragment or the F terminal hairpin/duplex/70bp tandem repeat fragment were separately ligated to either the left or right ITR fragment using DNA ligase at a 1 : 1 molar ratio overnight at l6°C.
  • the DNA ligase was subsequently heat inactivated at 65°C prior to being transfected into Shope Fibroma virus (SFV)-infected BGMK cells.
  • SFV Shope Fibroma virus
  • a 70bp repeat fragment that was identical to the VACV ACAM2000 strain was synthesized. Sapl and Nhel restriction sites were included at the 5’ and 3’ terminus of the 70bp tandem repeat fragment to facilitate the ligation onto the VACV ACAM2000 hairpin sequence and the VACV ACAM2000 right and left ITR fragments, respectively. Before the VACV ACAM2000 terminal hairpin loops could be ligated onto the 70bp tandem repeat fragment, the loop had to be extended an additional 58bp using a duplex sequence synthesized by IDT Technologies. This was due to the extra sequence being immediately downstream of the concatemer resolution site, prior to the first 70bp repeat sequence found in VACV strain ACAM2000.
  • the duplex sequence was produced by synthesizing two single-stranded DNA molecules that, when annealed together, would produce a duplex DNA molecule with a 5’- TGT overhang at the 5’ end and a 5’-GGT overhang at the 3’ end (SEQ ID NO: 119 and SEQ ID NO: 120). Since the VACV ACAM2000 F and S terminal hairpin loops generate a 3’ -AC A overhang at their terminal loops, the 58bp duplex was ligated to the hairpins to generate an ⁇ l30bp terminal hairpin loop. This hairpin/duplex fragment was gel purified and then subsequently ligated onto the Sapl digested end of the 70bp repeat fragment.
  • the 70bp tandem repeat was mixed with either an F terminal hairpin/duplex structure or a S terminal hairpin/duplex structure at a ⁇ 5-fold molar excess relative to the 70bp tandem repeat fragment in the presence of DNA ligase. This produced an upward shift in the DNA electrophoresis gel compared to the 70bp only reaction, indicating that the terminal hairpin/duplex was successfully ligated onto the 70bp tandem repeat fragment.
  • This terminal hairpin/duplex/70bp tandem repeat fragment was subsequently ligated onto the ACAM2000 left or right ITR fragment that had been previously modified at their terminal ends to include the Nhe I restriction site.
  • This left or right ITR fragment was digested, a 5’-CTAG overhang was left at their 5’ termini.
  • the Nhel site is used to directly ligate this fragment to the LITR and RITR regions of the VACV ACAM2000 DNA fragments.
  • the S terminal hairpin/duplex/70bp tandem repeat fragment or the F terminal hairpin/duplex/70bp tandem repeat fragment were separately ligated to either the left or right ITR fragment using DNA ligase at a 1 : 1 molar ratio overnight at l6°C.
  • the DNA ligase was subsequently heat inactivated at 65°C prior to being transfected into Shope Fibroma virus (SF V)-infected BGMK cells.
  • Each of the VACV ACAM2000 overlapping DNA fragments in Table 4 were cloned into a plasmid provided from GeneArt using the restriction enzyme I-Scel. Prior to transfection of these synthetic DNA fragments into BGMK cells, the plasmids were digested with I-Scel and the products were run on a gel to confirm that the DNA fragments were successfully linearized. Following digestion at 37°C for 2h, the reactions were subsequently heat-inactivated at 65°C. Samples were stored on ice or at 4°C until the terminal hairpin/duplex/70bp tandem repeat/ITR fragments were created (as described above).
  • SFV strain Kasza and BSC-40 were originally obtained from the American Type Culture Collection. Buffalo green monkey kidney (BGMK) cells were obtained from G. McFadden (University of Florida). BSC-40 and BGMK cells are propagated at 37°C in 5% C0 2 in minimal essential medium (MEM) supplemented with L-glutamine, nonessential amino acids, sodium pyruvate, antibiotics and antimycotics, and 5% fetal calf serum (FCS; ThermoFisher Scientific).
  • MEM minimal essential medium
  • FCS fetal calf serum
  • BGMK Buffalo green monkey kidney
  • Virus particles were recovered by scraping the infected cells into the cell culture medium and performing three cycles of freezing and thawing.
  • the crude extract was diluted 10 2 in serum- free MEM and 4ml of the inoculum is plated on 9 - 16 l50mm tissue culture plates of BSC-40 cells to recover reactivated scVACV ACAM2000 YFP-gpt: : l05.
  • One hour post infection the inoculum was replaced with MEM containing 5% FCS and 0.9% Noble Agar. Yellow fluorescent plaques were visualized under an inverted microscope and individual plaques were picked for further analysis.
  • scVACV ACAM2000 YFP-gpt : 105 plaques were plaque purified three times with yellow fluorescence selection.
  • the infected plates containing both SFV and VACV ACAM2000 clones were harvested, followed by three freeze thaw cycles to release virus, and then serially diluted and plated onto BSC-40 cells, which preferentially promote growth of the VACV ACAM2000 viruses compared to the SFV viruses.
  • Three rounds of plaque purification were performed followed by a bulkup of the virus stocks in 10 - 150 mm tissue culture plates. The virus was subsequently lysed from these cells and separated on a 36% sucrose cushion, followed by further purification on a 24% - 40% sucrose density gradient. Genomic DNA was isolated from these purified genomes and next generation Illumina sequencing was performed to confirm the sequence of the synthetic virus genomes.
  • VACV_ACAM2000 Two independent scVACV ACAM2000-WR DUP/HP clones plus a VACV_WRAJ2R control where the J2R gene sequence has been replaced with a YFP-gpt marker, and a wtVACV ACAM2000 control (VAC_ACAM2000) were purified and then left either undigested, digested with Bsal , Hindlll , or Notl and Pvul.
  • the isolated genomic DNA from both scVACV ACAM2000-WR DUP/HP and wtVACV ACAM2000 were digested with Bsal and Hindlll.
  • Contig 2 was 167,020 bp, and aligned with the central conserved region of the genome (nucleotide positions 19,467 to 186,486).
  • contig 3 was 16,322 bp, and corresponded to most of the ITR region (except for the tandem repeat sequences.
  • contig 1 was 167,020 bp, and aligned with the central conserved region of the genome (nucleotide positions 19,469 to 186,488).
  • Contig 2 was 16, 150 bp, and corresponded to most of the ITR region (except for tandem repeat sequences). When this contig was mapped to the reference genome in Snapgene, gaps in the sequence were observed at positions 2633 to 3417 and nucleotide positions 15,175 to 15220. The first gap region corresponds to the 54bp repeat region and it is most likely due to the inability to accurately assemble these regions using de novo assembly tools.
  • the Illumina reads were also mapped to a reference map in CLC Genomics.
  • the Illumina reads covered the full length of the reference sequence with an average coverage of 1925 and 2533, for clone 1 and 2 of scVACV ACAM2000-WR DUP/HP, respectively, and an average coverage of 2195 and 1602 for clone 1 and 2 of scVACV ACAM2000-ACAM2000 DUP/HP, respectively.
  • the sequencing data corroborates the in vitro genomic analysis data and confirms that scVACV ACAM20000-WR DUP/HP and scVACV ACAM2000-ACAM2000 DUP/HP were successfully reactivated in SFV-infected cells.
  • Human MSC are infected with the synthetic chimeric poxvirus, such as scHPXV, scVACV ACAM2000-WR DUP/HP or scVACV ACAM2000- ACAM2000 DUP/HP.
  • Cells are infected in serum-free media 2 hours at 37°C while in constant rotation to prevent cells from settling.
  • Cells are infected at multiplicity of infection (MOI) of 2 or 4.
  • MOI multiplicity of infection
  • MSC are gently pelleted and supernatant removed.
  • Cells are plated and allowed to incubate at 37°C for 48 hours. The percent of infected cells is determined by flow cytometry.
  • the oncolytic activity of MSCs loaded with the synthetic chimeric poxvirus is determined by using a specific highly or intermediately proliferating cell line or in vivo.
  • ADSCs Adipose-derived stem cells
  • Adipose tissue is an ideal source of mesenchymal stem cells.
  • Human adipose tissues are obtained from healthy donors as fat biopsies in an outpatient clinic. 2 cubic cm of subcutaneous fat is excised prior to incision of the fascia. The fat tissues are minced with surgical scalpels and incubated in 0.075% collagenase type I (Worthington Biochemical, Lakewood, NJ) for 90 min at 37°C.
  • Digested tissue is centrifuged at 400 g for 5 min with the pellet washed in PBS, passed through a 70 pm cell strainer (BD Biosciences, San Jose, CA), and incubated in red blood cell lysis buffer (154 mMNH4Cl, 10 mM KHC03, 0.1 mMEDTA).
  • Cells are grown in T-175 cm2 flasks at a concentration of 1.0-2.5 x l03 cells/cm2 in Advanced MEM with 5% PLTmax (Mill Creek Life Sciences, Rochester, MN), 100 U/ml penicillin, 100 g/ml streptomycin, and 2 mM L-glutamine (Invitrogen, Carlsbad, CA, USA) in a 37°C 5% C02 incubator for 3-4 days. When cells are 60-80% confluent, they are passaged using TrypLE (Trypsin Like Enzyme, Invitrogen). [0195] Cells are frozen in aliquots in liquid nitrogen and stored until use.
  • ADSCs are infected with the synthetic chimeric poxvirus, such as scHPXV, scVACV ACAM2000-WR DUP/HP or scVACV ACAM2000- ACAM2000 DUP/HP.
  • Cells are infected in serum-free media 2 hours at 37°C while in constant rotation to prevent cells from settling. Cells are infected at multiplicity of infection (MOI) of 2 or 4.
  • MOI multiplicity of infection
  • ADSCs are gently pelleted and supernatant removed. Cells are plated and allowed to incubate at 37°C for 48 hours. The percent of infected cells is determined by flow cytometry.
  • the oncolytic activity of ADSCs loaded with the synthetic chimeric poxvirus is determined by using a specific highly or intermediately proliferating cell line or in vivo.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PCT/US2019/030488 2018-05-02 2019-05-02 Stem cells comprising synthetic chimeric vaccinia virus and methods of using them Ceased WO2019213453A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA3098145A CA3098145A1 (en) 2018-05-02 2019-05-02 Stem cells comprising synthetic chimeric vaccinia virus and methods of using them
US17/049,741 US20210236619A1 (en) 2018-05-02 2019-05-02 Stem cells comprising synthetic chimeric vaccinia virus and methods of using them
EP19797026.2A EP3787681A4 (en) 2018-05-02 2019-05-02 Stem cells comprising synthetic chimeric vaccinia virus and methods of using them
AU2019262150A AU2019262150A1 (en) 2018-05-02 2019-05-02 Stem cells comprising synthetic chimeric vaccinia virus and methods of using them
CN201980029672.6A CN112261951A (zh) 2018-05-02 2019-05-02 包含合成嵌合痘苗病毒的干细胞及其使用方法
JP2020561064A JP2021522789A (ja) 2018-05-02 2019-05-02 合成キメラワクシニアウイルスを含む幹細胞およびそれらを使用する方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862666013P 2018-05-02 2018-05-02
US62/666,013 2018-05-02

Publications (1)

Publication Number Publication Date
WO2019213453A1 true WO2019213453A1 (en) 2019-11-07

Family

ID=68386182

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/030488 Ceased WO2019213453A1 (en) 2018-05-02 2019-05-02 Stem cells comprising synthetic chimeric vaccinia virus and methods of using them

Country Status (9)

Country Link
US (1) US20210236619A1 (https=)
EP (1) EP3787681A4 (https=)
JP (1) JP2021522789A (https=)
CN (1) CN112261951A (https=)
AR (1) AR115070A1 (https=)
AU (1) AU2019262150A1 (https=)
CA (1) CA3098145A1 (https=)
TW (1) TW202014200A (https=)
WO (1) WO2019213453A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2846551C1 (ru) * 2020-10-27 2025-09-09 Дэйтс Био Ко., Лтд. Мезенхимальные стволовые клетки, которые обеспечивают улучшение нацелевания на опухоль и массовое получение вирусов

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019535311A (ja) 2016-11-02 2019-12-12 デイビッド エバンス， 合成キメラポックスウイルス
EP3788142A4 (en) * 2018-05-02 2022-04-27 Tonix Pharma Holdings Limited SYNTHETIC CHIMERIC VACCINE VIRUS

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014160475A1 (en) * 2013-03-13 2014-10-02 Aboody Karen S Tropic cell based virotherapy for the treatment of cancer
WO2017027757A2 (en) * 2015-08-11 2017-02-16 StemImmune, Incorporated Smallpox vaccine for cancer treatment
WO2019043282A1 (es) * 2017-09-04 2019-03-07 Instituto De Salud Carlos Iii Producto de combinación que comprende una célula madre mesenquimal modificada y una sustancia antigénica

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2503717C2 (ru) * 2007-11-19 2014-01-10 Трансжене Са Поксвирусные онколитические векторы
CA2709292A1 (en) * 2009-07-10 2011-01-10 The Governors Of The University Of Alberta Oncolytic viruses and methods for treating neoplastic disorders
ES2848650T3 (es) * 2009-09-14 2021-08-11 Sillajen Biotherapeutics Inc Terapia combinada contra el cáncer con virus vaccinia oncolítico
WO2013083254A1 (en) * 2011-12-09 2013-06-13 Bavarian Nordic A/S Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c
CN107847534B (zh) * 2015-04-17 2022-10-04 纪念斯隆凯特琳癌症中心 Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用
CN105535993A (zh) * 2015-12-25 2016-05-04 浙江省人民医院 重组溶瘤痘苗病毒在治疗胃癌中的用途
WO2019213173A1 (en) * 2018-04-30 2019-11-07 City Of Hope Neural stem cell compositions including chimeric poxviruses for cancer treatment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014160475A1 (en) * 2013-03-13 2014-10-02 Aboody Karen S Tropic cell based virotherapy for the treatment of cancer
WO2017027757A2 (en) * 2015-08-11 2017-02-16 StemImmune, Incorporated Smallpox vaccine for cancer treatment
WO2019043282A1 (es) * 2017-09-04 2019-03-07 Instituto De Salud Carlos Iii Producto de combinación que comprende una célula madre mesenquimal modificada y una sustancia antigénica

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DRAGANOV DD ET AL.: "Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers", JOURNAL OF TRANSLATIONAL MEDICINE, vol. 17, 27 March 2019 (2019-03-27), pages 100, XP002795494, Retrieved from the Internet <URL:https://doi.org/10.1]86/s12967-019-1829-z> *
GUO ZS ET AL.: "Oncolytic Virotherapy: Molecular Targets in Tumor-Selective Replication and Carrier Cell -Mediated Delivery of Oncolytic Viruses", BIOCHIM BIOPHYS ACTA, vol. 1785, no. 2, 2008, pages 217 - 231, XP022615368, DOI: 10.1016/j.bbcan.2008.02.001 *
KIM J ET AL.: "Stem Cell -Based Cell Carrier for Targeted Oncolytic Virotherapy: Translational Opportunity and Open Questions", VIRUSES, vol. 7, no. 12, 2015, pages 6200 - 6217, XP055636651, DOI: 10.3390/v7122921 *
MOHAMED A A HAMMAD , CONNOR BURKE , NANHAI CHEN , JAMMING LU , HUMAN , FONG , KAREN ABOODY : "Abstract 263: Neural Stem Cell Delivery of a Chimeric Orthopoxvirus in Combination with PD-1 Antibody for the Treatment of Metastatic Ovarian Cancer in Mice", MOLECULAR THERAPY, vol. 27, no. 4S1, 22 April 2019 (2019-04-22), pages 127 - 128, XP009524565 *
NOYCE RS ET AL.: "Construction of an infectious horsepox virus vaccine from chemically synthesized DNA fragments", PLOS ONE, vol. 13, no. 1, January 2018 (2018-01-01), pages 1 - 16, XP055648704, DOI: 10.1371/journal.pone.0188453 *
RAMÍREZ M ET AL.: "Patient-derived mesenchymal stem cells as delivery vehicles for oncolytic virotherapy: novel state-of-the-art technology", ONCOLYTIC VIROTHERAPY, vol. 4, October 2015 (2015-10-01), pages 149 - 155, XP055649910 *
See also references of EP3787681A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2846551C1 (ru) * 2020-10-27 2025-09-09 Дэйтс Био Ко., Лтд. Мезенхимальные стволовые клетки, которые обеспечивают улучшение нацелевания на опухоль и массовое получение вирусов

Also Published As

Publication number Publication date
AU2019262150A1 (en) 2020-11-19
CN112261951A (zh) 2021-01-22
CA3098145A1 (en) 2019-11-07
TW202014200A (zh) 2020-04-16
AR115070A1 (es) 2020-11-25
US20210236619A1 (en) 2021-08-05
JP2021522789A (ja) 2021-09-02
EP3787681A4 (en) 2022-01-19
EP3787681A1 (en) 2021-03-10

Similar Documents

Publication Publication Date Title
US12365879B2 (en) Synthetic chimeric poxviruses
US12529036B2 (en) Synthetic chimeric vaccinia virus
AU2021226592A1 (en) Recombinant poxvirus based vaccine against SARS-CoV-2 virus
US20210236619A1 (en) Stem cells comprising synthetic chimeric vaccinia virus and methods of using them
US20040014034A1 (en) Method of producing a recombinant virus
HK40014109A (en) Synthetic chimeric poxviruses
HK40014109B (zh) 合成嵌合痘病毒
WO2023168286A1 (en) Recombinant poxvirus based vaccine against the omicron strain of sars-cov-2 virus and variants thereof
Holley Mechanistic Constraints on the Formation of Virion Morphotypes in Vaccinia Virus

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19797026

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3098145

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2020561064

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019262150

Country of ref document: AU

Date of ref document: 20190502

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2019797026

Country of ref document: EP

Effective date: 20201202